Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 1/2019

01.12.2019 | Spondyloarthritiden | Leitlinien

Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019

Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen*

verfasst von: PD Dr. med. U. Kiltz, Prof. Dr. med. J. Braun, Prof. Dr. med. A. Becker, Prof. Dr. med. J.-F. Chenot, PD Dr. med. M. Dreimann, L. Hammel, Prof. Dr. med. A. Heiligenhaus, PD Dr. med. K.‑G. Hermann, Prof. Dr. med. Dipl. Phys. R. Klett, PD Dr. med. D. Krause, Prof. Dr. med. K.‑F. Kreitner, Prof. Dr. med. U. Lange, A. Lauterbach, Prof. Dr. med. W. Mau, Prof. Dr. med. R. Mössner, Dr. med. U. Oberschelp, Dr. med. S. Philipp, Prof. Dr. med. U. Pleyer, Prof. Dr. med. M. Rudwaleit, Dr. med. E. Schneider, Prof. Dr. med. T. L. Schulte, Prof. Dr. med. em. J. Sieper, Prof. Dr. med. A. Stallmach, Prof. Dr. med. B. Swoboda, Prof. Dr. med. M. Winking, DGRh, DEGAM, DWG, DVMB, DOG, DRG, DGMM, DGPMR/DGRW, Physio Deutschland, DDG, DGOOC, DGIM, DGOOC/DGORh, DGNC

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Auszug

Version: 2018 …
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Die Mehrzahl der in dieser Leitlinie genannten Studien bezieht sich auf Patienten mit AS. Gerade in jüngster Zeit sind aber auch viele Studien, die Patienten mit nr-axSpA umfassen, publiziert worden. Im klinischen Alltag hat diese artifizielle Einteilung nur eine untergeordnete Bedeutung und spielt im Wesentlichen eine Rolle bei der Indikation für eine Biologikatherapie. Die überwiegende Anzahl der medikamentösen Therapien ist in Deutschland für Patienten mit AS. Seit 2012 sind bis auf Infliximab alle TNFi für die Behandlung symptomatischer Patienten mit nr-axSpA und objektivem Entzündungsnachweis* zugelassen (Abschn. 8.4.2) (*Die modifizierten New-York-Kriterien dienen zur Charakterisierung des röntgenologischen Stadiums und werden im Abschn. 4.2 und 6.1.1.1 näher erläutert).
 
2
Die Zulassungsstudie zur nr-axSpA wird gerade durchgeführt.
 
3
Nach Fertigstellung der SLR wurde eine kontrollierte Studie bei Patienten mit nr-axSpA publiziert, in der gezeigt wurde, dass bei Patienten in klinischer Remission unter einer Therapie mit Adalimumab das Absetzen der bDMARD-Therapie zwar zu einer höheren Rate an Schüben führte, aber dass trotzdem 47 % der Patienten in dem Beobachtungszeitraum keinen Schub erlitten [516].
 
Literatur
2.
Zurück zum Zitat Rudwaleit M et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783 PubMedCrossRef Rudwaleit M et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783 PubMedCrossRef
3.
Zurück zum Zitat Rudwaleit M et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68(6):770–776 PubMedCrossRef Rudwaleit M et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68(6):770–776 PubMedCrossRef
4.
Zurück zum Zitat Dean LE et al (2014) Global prevalence of ankylosing spondylitis. Rheumatol (oxford) 53(4):650–657 CrossRef Dean LE et al (2014) Global prevalence of ankylosing spondylitis. Rheumatol (oxford) 53(4):650–657 CrossRef
5.
Zurück zum Zitat Braun J et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58–67 PubMedCrossRef Braun J et al (1998) Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 41(1):58–67 PubMedCrossRef
6.
Zurück zum Zitat Almodovar R et al (2011) Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). Clin Exp Rheumatol 29(5):822–827 PubMed Almodovar R et al (2011) Phenotypic differences between familial versus sporadic ankylosing spondylitis: a cross-sectional Spanish registry of spondyloarthropathies (REGISPONSER). Clin Exp Rheumatol 29(5):822–827 PubMed
7.
Zurück zum Zitat Chen HA et al (2012) Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol 39(5):1013–1018 PubMedCrossRef Chen HA et al (2012) Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol 39(5):1013–1018 PubMedCrossRef
8.
Zurück zum Zitat Jamalyaria F et al (2017) Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol 36(10):2359–2364 PubMedPubMedCentralCrossRef Jamalyaria F et al (2017) Ethnicity and disease severity in ankylosing spondylitis a cross-sectional analysis of three ethnic groups. Clin Rheumatol 36(10):2359–2364 PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Skare TL et al (2012) Effect of age at disease onset in the clinical profile of spondyloarthritis: a study of 1424 Brazilian patients. Clin Exp Rheumatol 30(3):351–357 PubMed Skare TL et al (2012) Effect of age at disease onset in the clinical profile of spondyloarthritis: a study of 1424 Brazilian patients. Clin Exp Rheumatol 30(3):351–357 PubMed
10.
Zurück zum Zitat Landewe R et al (2009) Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 68(6):863–867 PubMedCrossRef Landewe R et al (2009) Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 68(6):863–867 PubMedCrossRef
11.
Zurück zum Zitat Ward MM et al (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59(4):497–503 PubMedCrossRef Ward MM et al (2008) Impact of ankylosing spondylitis on work and family life: comparisons with the US population. Arthritis Rheum 59(4):497–503 PubMedCrossRef
12.
Zurück zum Zitat Dagfinrud H et al (2005) Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 32(3):516–523 PubMed Dagfinrud H et al (2005) Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 32(3):516–523 PubMed
13.
Zurück zum Zitat Mau W et al (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32(4):721–728 PubMed Mau W et al (2005) Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32(4):721–728 PubMed
14.
Zurück zum Zitat Boonen A et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69(6):1123–1128 PubMedCrossRef Boonen A et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69(6):1123–1128 PubMedCrossRef
15.
Zurück zum Zitat Calin A et al (1980) The prevalence and nature of back pain in an industrial complex: a questionnaire and radiographic and HLA analysis. Spine (phila Pa 1976) 5(2):201–205 CrossRef Calin A et al (1980) The prevalence and nature of back pain in an industrial complex: a questionnaire and radiographic and HLA analysis. Spine (phila Pa 1976) 5(2):201–205 CrossRef
16.
Zurück zum Zitat Feldtkeller E et al (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66 PubMedCrossRef Feldtkeller E et al (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66 PubMedCrossRef
17.
Zurück zum Zitat van der Linden SM et al (1984) The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 27(3):241–249 PubMedCrossRef van der Linden SM et al (1984) The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 27(3):241–249 PubMedCrossRef
18.
Zurück zum Zitat Sorensen J, Hetland ML, D. all departments of rheumatology (2015) in, Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74(3):e12 PubMedCrossRef Sorensen J, Hetland ML, D. all departments of rheumatology (2015) in, Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 74(3):e12 PubMedCrossRef
19.
Zurück zum Zitat Burgos-Varga R et al (2016) The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. Arthritis Res Ther 18(1):132 PubMedPubMedCentralCrossRef Burgos-Varga R et al (2016) The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study. Arthritis Res Ther 18(1):132 PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Zink A et al (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613–622 PubMed Zink A et al (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis—results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27(3):613–622 PubMed
21.
Zurück zum Zitat van der Heijde D et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991 PubMedCrossRef van der Heijde D et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991 PubMedCrossRef
22.
Zurück zum Zitat Rojas-Vargas M et al (2009) First signs and symptoms of spondyloarthritis—data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatol (oxford) 48(4):404–409 CrossRef Rojas-Vargas M et al (2009) First signs and symptoms of spondyloarthritis—data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). Rheumatol (oxford) 48(4):404–409 CrossRef
23.
Zurück zum Zitat Hamilton L et al (2014) The prevalence of inflammatory back pain in a UK primary care population. Rheumatol (oxford) 53(1):161–164 CrossRef Hamilton L et al (2014) The prevalence of inflammatory back pain in a UK primary care population. Rheumatol (oxford) 53(1):161–164 CrossRef
24.
Zurück zum Zitat Calin A et al (1977) Clinical history as a screening test for ankylosing spondylitis. JAMA 237(24):2613–2614 PubMedCrossRef Calin A et al (1977) Clinical history as a screening test for ankylosing spondylitis. JAMA 237(24):2613–2614 PubMedCrossRef
25.
Zurück zum Zitat Rudwaleit M et al (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54(2):569–578 PubMedCrossRef Rudwaleit M et al (2006) Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 54(2):569–578 PubMedCrossRef
26.
Zurück zum Zitat Sieper J et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68(6):784–788 PubMedCrossRef Sieper J et al (2009) New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 68(6):784–788 PubMedCrossRef
27.
Zurück zum Zitat Solmaz D et al (2014) Performance of different criteria sets for inflammatory back pain in patients with axial spondyloarthritis with and without radiographic sacroiliitis. Clin Rheumatol 33(10):1475–1479 PubMedCrossRef Solmaz D et al (2014) Performance of different criteria sets for inflammatory back pain in patients with axial spondyloarthritis with and without radiographic sacroiliitis. Clin Rheumatol 33(10):1475–1479 PubMedCrossRef
28.
Zurück zum Zitat Gazeau P et al (2018) Classification criteria versus physician’s opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. Joint Bone Spine 85(1):85–91 PubMedCrossRef Gazeau P et al (2018) Classification criteria versus physician’s opinion for considering a patient with inflammatory back pain as suffering from spondyloarthritis. Joint Bone Spine 85(1):85–91 PubMedCrossRef
29.
Zurück zum Zitat Machado P et al (2010) Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 69(8):1465–1470 PubMedCrossRef Machado P et al (2010) Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 69(8):1465–1470 PubMedCrossRef
30.
Zurück zum Zitat Weber U et al (2012) Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional study. Arthritis Res Ther 14(1):R3 PubMedPubMedCentralCrossRef Weber U et al (2012) Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional study. Arthritis Res Ther 14(1):R3 PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Payet J et al (2012) Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients. Clin Exp Rheumatol 30(2):191–196 PubMed Payet J et al (2012) Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients. Clin Exp Rheumatol 30(2):191–196 PubMed
32.
Zurück zum Zitat Navarro-Compan V et al (2015) Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. Arthritis Res Ther 17:265 PubMedPubMedCentralCrossRef Navarro-Compan V et al (2015) Sponyloarthritis features forecasting the presence of HLA-B27 or sacroiliitis on magnetic resonance imaging in patients with suspected axial spondyloarthritis: results from a cross-sectional study in the ESPeranza Cohort. Arthritis Res Ther 17:265 PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Bethi S et al (2013) Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (hoboken) 65(4):607–614 CrossRef Bethi S et al (2013) Functional limitations due to axial and peripheral joint impairments in patients with ankylosing spondylitis: are focused measures more informative? Arthritis Care Res (hoboken) 65(4):607–614 CrossRef
34.
Zurück zum Zitat Aydin SZ et al (2016) A relationship between spinal new bone formation in ankylosing spondylitis and the sonographically determined Achilles tendon enthesophytes. Rheumatol Int 36(3):397–404 PubMedCrossRef Aydin SZ et al (2016) A relationship between spinal new bone formation in ankylosing spondylitis and the sonographically determined Achilles tendon enthesophytes. Rheumatol Int 36(3):397–404 PubMedCrossRef
35.
Zurück zum Zitat Ruta S et al (2011) Prevalence of subclinical enthesopathy in patients with spondyloarthropathy: an ultrasound study. J Clin Rheumatol 17(1):18–22 PubMedCrossRef Ruta S et al (2011) Prevalence of subclinical enthesopathy in patients with spondyloarthropathy: an ultrasound study. J Clin Rheumatol 17(1):18–22 PubMedCrossRef
36.
Zurück zum Zitat Maksymowych WP et al (2009) Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 68(6):948–953 PubMedCrossRef Maksymowych WP et al (2009) Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 68(6):948–953 PubMedCrossRef
37.
Zurück zum Zitat Heuft-Dorenbosch L et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132 PubMedCrossRef Heuft-Dorenbosch L et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132 PubMedCrossRef
38.
Zurück zum Zitat Tournadre A et al (2013) Differences between women and men with recent onset axial spondyloarthritis: results from the DESIR cohort. Arthritis Care Res (hoboken) 65(9):1482–1489 CrossRef Tournadre A et al (2013) Differences between women and men with recent onset axial spondyloarthritis: results from the DESIR cohort. Arthritis Care Res (hoboken) 65(9):1482–1489 CrossRef
39.
Zurück zum Zitat Webers C et al (2016) Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatol (oxford) 55(3):419–428 Webers C et al (2016) Gender-attributable differences in outcome of ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study. Rheumatol (oxford) 55(3):419–428
40.
Zurück zum Zitat van der Horst-Bruinsma IE et al (2013) Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis 72(7):1221–1224 PubMedCrossRef van der Horst-Bruinsma IE et al (2013) Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis 72(7):1221–1224 PubMedCrossRef
41.
Zurück zum Zitat Landi M et al (2016) Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine (Baltimore) 95(51):e5652 CrossRef Landi M et al (2016) Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine (Baltimore) 95(51):e5652 CrossRef
42.
Zurück zum Zitat Sidiropoulos PI et al (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatol (oxford) 47(3):355–361 CrossRef Sidiropoulos PI et al (2008) Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. Rheumatol (oxford) 47(3):355–361 CrossRef
44.
Zurück zum Zitat Karberg K et al (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32(7):1290–1298 PubMed Karberg K et al (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32(7):1290–1298 PubMed
45.
Zurück zum Zitat Wang D et al (2017) Bone edema on magnetic resonance imaging is highly associated with low bone mineral density in patients with ankylosing spondylitis. PLoS ONE 12(12):e189569 PubMedPubMedCentralCrossRef Wang D et al (2017) Bone edema on magnetic resonance imaging is highly associated with low bone mineral density in patients with ankylosing spondylitis. PLoS ONE 12(12):e189569 PubMedPubMedCentralCrossRef
46.
Zurück zum Zitat Briot K et al (2016) Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Rheumatol (oxford) 55(2):335–342 CrossRef Briot K et al (2016) Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Rheumatol (oxford) 55(2):335–342 CrossRef
47.
Zurück zum Zitat Gratacos J et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42(11):2319–2324 PubMedCrossRef Gratacos J et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42(11):2319–2324 PubMedCrossRef
48.
Zurück zum Zitat Prieto-Alhambra D et al (2015) Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study. Osteoporos Int 26(1):85–91 PubMedCrossRef Prieto-Alhambra D et al (2015) Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study. Osteoporos Int 26(1):85–91 PubMedCrossRef
49.
Zurück zum Zitat Jun JB et al (2006) Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 33(8):1637–1641 PubMed Jun JB et al (2006) Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 33(8):1637–1641 PubMed
50.
Zurück zum Zitat Vosse D et al (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 68(12):1839–1842 PubMedCrossRef Vosse D et al (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 68(12):1839–1842 PubMedCrossRef
51.
Zurück zum Zitat Deminger A et al (2017) Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. Arthritis Res Ther 19(1):273 PubMedPubMedCentralCrossRef Deminger A et al (2017) Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. Arthritis Res Ther 19(1):273 PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Montala N et al (2011) Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 38(5):893–897 PubMedCrossRef Montala N et al (2011) Prevalence of vertebral fractures by semiautomated morphometry in patients with ankylosing spondylitis. J Rheumatol 38(5):893–897 PubMedCrossRef
53.
Zurück zum Zitat Westerveld LA, Verlaan JJ, Oner FC (2009) Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. Eur Spine J 18(2):145–156 PubMedCrossRef Westerveld LA, Verlaan JJ, Oner FC (2009) Spinal fractures in patients with ankylosing spinal disorders: a systematic review of the literature on treatment, neurological status and complications. Eur Spine J 18(2):145–156 PubMedCrossRef
54.
Zurück zum Zitat Dursun N et al (2015) Risk of falls in patients with ankylosing spondylitis. J Clin Rheumatol 21(2):76–80 PubMedCrossRef Dursun N et al (2015) Risk of falls in patients with ankylosing spondylitis. J Clin Rheumatol 21(2):76–80 PubMedCrossRef
55.
Zurück zum Zitat Protopopov M et al (2017) Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Res Ther 19(1):240 PubMedPubMedCentralCrossRef Protopopov M et al (2017) Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Res Ther 19(1):240 PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Haywood KL et al (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatol (oxford) 43(6):750–757 CrossRef Haywood KL et al (2004) Spinal mobility in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatol (oxford) 43(6):750–757 CrossRef
57.
Zurück zum Zitat Wanders A et al (2005) Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 64(7):988–994 PubMedPubMedCentralCrossRef Wanders A et al (2005) Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 64(7):988–994 PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Heuft-Dorenbosch L et al (2004) Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. J Rheumatol 31(9):1779–1784 PubMed Heuft-Dorenbosch L et al (2004) Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. J Rheumatol 31(9):1779–1784 PubMed
59.
Zurück zum Zitat Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12(4 Suppl):142S–158S PubMedCrossRef Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12(4 Suppl):142S–158S PubMedCrossRef
60.
Zurück zum Zitat Pile KD et al (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30(1):29–34 PubMedCrossRef Pile KD et al (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30(1):29–34 PubMedCrossRef
61.
Zurück zum Zitat Gladman DD et al (2007) International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 34(8):1733–1739 PubMed Gladman DD et al (2007) International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 34(8):1733–1739 PubMed
62.
Zurück zum Zitat Kennedy LG et al (1995) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34(8):767–770 PubMedCrossRef Kennedy LG et al (1995) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34(8):767–770 PubMedCrossRef
63.
Zurück zum Zitat Chandran V et al (2007) Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. J Rheumatol 34(12):2463–2465 PubMed Chandran V et al (2007) Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. J Rheumatol 34(12):2463–2465 PubMed
64.
Zurück zum Zitat Shin JK et al (2014) Correlation between clinical outcome and spinopelvic parameters in ankylosing spondylitis. Eur Spine J 23(1):242–247 PubMedCrossRef Shin JK et al (2014) Correlation between clinical outcome and spinopelvic parameters in ankylosing spondylitis. Eur Spine J 23(1):242–247 PubMedCrossRef
65.
Zurück zum Zitat Jenkinson TR et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698 PubMed Jenkinson TR et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698 PubMed
66.
Zurück zum Zitat Calin A et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285 PubMed Calin A et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285 PubMed
67.
Zurück zum Zitat Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291 PubMed Garrett S et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291 PubMed
68.
Zurück zum Zitat Ruof J, Sangha O, Stucki G (1999) Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 58(4):218–225 PubMedCrossRef Ruof J, Sangha O, Stucki G (1999) Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 58(4):218–225 PubMedCrossRef
69.
Zurück zum Zitat Boonen A et al (2009) Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol 36(6):1249–1255 PubMedCrossRef Boonen A et al (2009) Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcome. J Rheumatol 36(6):1249–1255 PubMedCrossRef
70.
Zurück zum Zitat Ward MM et al (2005) Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 53(5):710–717 PubMedPubMedCentralCrossRef Ward MM et al (2005) Risk factors for functional limitations in patients with long-standing ankylosing spondylitis. Arthritis Rheum 53(5):710–717 PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Daltroy LH et al (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17(7):946–950 PubMed Daltroy LH et al (1990) A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17(7):946–950 PubMed
72.
Zurück zum Zitat Vander Cruyssen B et al (2007) The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 66(8):1072–1077 PubMedCrossRef Vander Cruyssen B et al (2007) The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 66(8):1072–1077 PubMedCrossRef
73.
Zurück zum Zitat Brophy S, Calin A (2001) Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 28(10):2283–2288 PubMed Brophy S, Calin A (2001) Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol 28(10):2283–2288 PubMed
74.
Zurück zum Zitat Rudwaleit M et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727 PubMedCrossRef Rudwaleit M et al (2009) The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 60(3):717–727 PubMedCrossRef
75.
Zurück zum Zitat Kiltz U et al (2012) Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (hoboken) 64(9):1415–1422 CrossRef Kiltz U et al (2012) Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (hoboken) 64(9):1415–1422 CrossRef
76.
Zurück zum Zitat Stolwijk C et al (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74(1):65–73 PubMedCrossRef Stolwijk C et al (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74(1):65–73 PubMedCrossRef
77.
Zurück zum Zitat Collantes E et al (2007) Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatol (oxford) 46(8):1309–1315 CrossRef Collantes E et al (2007) Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatol (oxford) 46(8):1309–1315 CrossRef
78.
Zurück zum Zitat Bremander A et al (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (hoboken) 63(4):550–556 CrossRef Bremander A et al (2011) Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (hoboken) 63(4):550–556 CrossRef
79.
Zurück zum Zitat Chorus AM et al (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62(12):1178–1184 PubMedPubMedCentralCrossRef Chorus AM et al (2003) Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 62(12):1178–1184 PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Sampaio-Barros PD et al (2013) An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. Clin Exp Rheumatol 31(4):484–489 PubMed Sampaio-Barros PD et al (2013) An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. Clin Exp Rheumatol 31(4):484–489 PubMed
81.
Zurück zum Zitat Canoui-Poitrine F et al (2012) Prevalence and factors associated with uveitis in spondylarthritis patients in France: results from an observational survey. Arthritis Care Res (hoboken) 64(6):919–924 CrossRef Canoui-Poitrine F et al (2012) Prevalence and factors associated with uveitis in spondylarthritis patients in France: results from an observational survey. Arthritis Care Res (hoboken) 64(6):919–924 CrossRef
82.
Zurück zum Zitat Zeboulon N, Dougados M, Gossec L (2008) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67(7):955–959 PubMedCrossRef Zeboulon N, Dougados M, Gossec L (2008) Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 67(7):955–959 PubMedCrossRef
83.
Zurück zum Zitat Essers I et al (2015) Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatol (oxford) 54(4):633–640 CrossRef Essers I et al (2015) Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatol (oxford) 54(4):633–640 CrossRef
84.
Zurück zum Zitat Robinson PC et al (2015) Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol 67(1):140–151 PubMedPubMedCentralCrossRef Robinson PC et al (2015) Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol 67(1):140–151 PubMedPubMedCentralCrossRef
85.
Zurück zum Zitat Rosenbaum JT (1992) Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 18(1):143–151 PubMed Rosenbaum JT (1992) Acute anterior uveitis and spondyloarthropathies. Rheum Dis Clin North Am 18(1):143–151 PubMed
86.
Zurück zum Zitat Accorinti M et al (2010) Clinical features and prognosis of HLA B27-associated acute anterior uveitis in an Italian patient population. Ocul Immunol Inflamm 18(2):91–96 PubMedCrossRef Accorinti M et al (2010) Clinical features and prognosis of HLA B27-associated acute anterior uveitis in an Italian patient population. Ocul Immunol Inflamm 18(2):91–96 PubMedCrossRef
87.
Zurück zum Zitat Munoz-Fernandez S et al (2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30(6):1277–1279 PubMed Munoz-Fernandez S et al (2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30(6):1277–1279 PubMed
88.
Zurück zum Zitat Benitez-Del-Castillo JM et al (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 14(Pt 3A):340–343 CrossRef Benitez-Del-Castillo JM et al (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 14(Pt 3A):340–343 CrossRef
89.
Zurück zum Zitat Nguyen QD et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192 PubMedCrossRef Nguyen QD et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192 PubMedCrossRef
90.
Zurück zum Zitat Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451 PubMedCrossRef Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451 PubMedCrossRef
91.
Zurück zum Zitat Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229 PubMedCrossRef Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229 PubMedCrossRef
92.
Zurück zum Zitat Gao X et al (2012) Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ 15(6):1054–1063 PubMedCrossRef Gao X et al (2012) Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ 15(6):1054–1063 PubMedCrossRef
93.
Zurück zum Zitat Lie E et al (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 76(9):1515–1521 PubMedCrossRef Lie E et al (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 76(9):1515–1521 PubMedCrossRef
94.
Zurück zum Zitat Wendling D et al (2014) Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 30(12):2515–2521 PubMedCrossRef Wendling D et al (2014) Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database. Curr Med Res Opin 30(12):2515–2521 PubMedCrossRef
95.
Zurück zum Zitat Rudwaleit M et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701 PubMedCrossRef Rudwaleit M et al (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 68(5):696–701 PubMedCrossRef
96.
Zurück zum Zitat Dick AD et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787 PubMedCrossRef Dick AD et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777–787 PubMedCrossRef
97.
Zurück zum Zitat Letko E et al (2015) Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 122(5):939–948 PubMedCrossRef Letko E et al (2015) Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology 122(5):939–948 PubMedCrossRef
98.
Zurück zum Zitat Mielants H et al (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10(1):147–164 PubMedCrossRef Mielants H et al (1996) Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol 10(1):147–164 PubMedCrossRef
99.
Zurück zum Zitat Mielants H et al (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22(12):2279–2284 PubMed Mielants H et al (1995) The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 22(12):2279–2284 PubMed
100.
Zurück zum Zitat D’Inca R et al (2009) Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis 41(8):565–569 PubMedCrossRef D’Inca R et al (2009) Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig Liver Dis 41(8):565–569 PubMedCrossRef
101.
Zurück zum Zitat Peeters H et al (2008) Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol 23(1):132–137 PubMed Peeters H et al (2008) Clinical and genetic factors associated with sacroiliitis in Crohn’s disease. J Gastroenterol Hepatol 23(1):132–137 PubMed
102.
Zurück zum Zitat Vavricka SR et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106(1):110–119 PubMedCrossRef Vavricka SR et al (2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 106(1):110–119 PubMedCrossRef
103.
Zurück zum Zitat El Miedany Y et al (2006) The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101(2):311–317 PubMedCrossRef El Miedany Y et al (2006) The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 101(2):311–317 PubMedCrossRef
104.
Zurück zum Zitat Hoffmann JC et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146 PubMedCrossRef Hoffmann JC et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146 PubMedCrossRef
105.
Zurück zum Zitat Braun J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647 PubMedCrossRef Braun J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647 PubMedCrossRef
106.
Zurück zum Zitat Toussirot E et al (2012) Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine 79(5):457–463 PubMedCrossRef Toussirot E et al (2012) Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease. A nationwide series. Joint Bone Spine 79(5):457–463 PubMedCrossRef
107.
Zurück zum Zitat Hueber W et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12):1693–1700 PubMedCrossRef Hueber W et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61(12):1693–1700 PubMedCrossRef
108.
Zurück zum Zitat Bergfeldt L et al (1982) Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker-treated men. Am J Med 73(2):187–191 PubMedCrossRef Bergfeldt L et al (1982) Ankylosing spondylitis: an important cause of severe disturbances of the cardiac conduction system. Prevalence among 223 pacemaker-treated men. Am J Med 73(2):187–191 PubMedCrossRef
110.
Zurück zum Zitat Bengtsson K et al (2018) Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. Ann Rheum Dis 77(4):541–548 PubMedCrossRef Bengtsson K et al (2018) Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. Ann Rheum Dis 77(4):541–548 PubMedCrossRef
111.
Zurück zum Zitat Sampaio-Barros PD et al (2007) Pulmonary involvement in ankylosing spondylitis. Clin Rheumatol 26(2):225–230 PubMedCrossRef Sampaio-Barros PD et al (2007) Pulmonary involvement in ankylosing spondylitis. Clin Rheumatol 26(2):225–230 PubMedCrossRef
112.
Zurück zum Zitat El Maghraoui A et al (2004) Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin Rheumatol 23(2):123–128 PubMedCrossRef El Maghraoui A et al (2004) Lung findings on thoracic high-resolution computed tomography in patients with ankylosing spondylitis. Correlations with disease duration, clinical findings and pulmonary function testing. Clin Rheumatol 23(2):123–128 PubMedCrossRef
113.
Zurück zum Zitat Souza AS Jr. et al (2004) Pulmonary abnormalities in ankylosing spondylitis: inspiratory and expiratory high-resolution CT findings in 17 patients. J Thorac Imaging 19(4):259–263 PubMedCrossRef Souza AS Jr. et al (2004) Pulmonary abnormalities in ankylosing spondylitis: inspiratory and expiratory high-resolution CT findings in 17 patients. J Thorac Imaging 19(4):259–263 PubMedCrossRef
114.
Zurück zum Zitat Gratacos J et al (1997) Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 24(5):912–915 PubMed Gratacos J et al (1997) Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 24(5):912–915 PubMed
115.
Zurück zum Zitat Lee SH et al (2013) Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33(7):1689–1692 PubMedCrossRef Lee SH et al (2013) Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int 33(7):1689–1692 PubMedCrossRef
116.
Zurück zum Zitat Jakobsen AK et al (2014) Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS ONE 9(11):e113602 PubMedPubMedCentralCrossRef Jakobsen AK et al (2014) Is nephrolithiasis an unrecognized extra-articular manifestation in ankylosing spondylitis? A prospective population-based Swedish national cohort study with matched general population comparator subjects. PLoS ONE 9(11):e113602 PubMedPubMedCentralCrossRef
117.
Zurück zum Zitat Molto A et al (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 75(6):1016–1023 PubMedCrossRef Molto A et al (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis 75(6):1016–1023 PubMedCrossRef
118.
Zurück zum Zitat Hmamouchi I et al (2016) Vitamin D, disease activity and comorbidities in early spondyloarthritis. Clin Exp Rheumatol 34(3):396–403 PubMed Hmamouchi I et al (2016) Vitamin D, disease activity and comorbidities in early spondyloarthritis. Clin Exp Rheumatol 34(3):396–403 PubMed
119.
Zurück zum Zitat Meesters JJ et al (2014) The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 16(5):418 PubMedPubMedCentralCrossRef Meesters JJ et al (2014) The risk for depression in patients with ankylosing spondylitis: a population-based cohort study. Arthritis Res Ther 16(5):418 PubMedPubMedCentralCrossRef
120.
Zurück zum Zitat Li Y et al (2012) Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study. Arthritis Res Ther 14(5):R215 PubMedPubMedCentralCrossRef Li Y et al (2012) Sleep disturbances are associated with increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-control study. Arthritis Res Ther 14(5):R215 PubMedPubMedCentralCrossRef
121.
Zurück zum Zitat Dhakad U et al (2015) Sexual dysfunctions and lower urinary tract symptoms in ankylosing spondylitis. Int J Rheum Dis 18(8):866–872 PubMedCrossRef Dhakad U et al (2015) Sexual dysfunctions and lower urinary tract symptoms in ankylosing spondylitis. Int J Rheum Dis 18(8):866–872 PubMedCrossRef
122.
Zurück zum Zitat Dau JD et al (2018) Opioid analgesic use in patients with Ankylosing Spondylitis: an analysis of the prospective study of outcomes in an Ankylosing Spondylitis cohort. J Rheumatol 45(2):188–194 PubMedCrossRef Dau JD et al (2018) Opioid analgesic use in patients with Ankylosing Spondylitis: an analysis of the prospective study of outcomes in an Ankylosing Spondylitis cohort. J Rheumatol 45(2):188–194 PubMedCrossRef
123.
Zurück zum Zitat Maas F et al (2016) Obesity is common in axial Spondyloarthritis and is associated with poor clinical outcome. J Rheumatol 43(2):383–387 PubMedCrossRef Maas F et al (2016) Obesity is common in axial Spondyloarthritis and is associated with poor clinical outcome. J Rheumatol 43(2):383–387 PubMedCrossRef
124.
Zurück zum Zitat Baraliakos X et al (2018) Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatol (oxford) 57(9):1541–1547 CrossRef Baraliakos X et al (2018) Patients with fibromyalgia rarely fulfil classification criteria for axial spondyloarthritis. Rheumatol (oxford) 57(9):1541–1547 CrossRef
125.
Zurück zum Zitat Molto A et al (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77(4):533–540 PubMedCrossRef Molto A et al (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study. Ann Rheum Dis 77(4):533–540 PubMedCrossRef
126.
Zurück zum Zitat Macfarlane GJ et al (2017) Co-occurrence and characteristics of patients with axial Spondyloarthritis who meet criteria for Fibromyalgia: results from a UK national register. Arthritis Rheumatol 69(11):2144–2150 PubMedCrossRef Macfarlane GJ et al (2017) Co-occurrence and characteristics of patients with axial Spondyloarthritis who meet criteria for Fibromyalgia: results from a UK national register. Arthritis Rheumatol 69(11):2144–2150 PubMedCrossRef
127.
Zurück zum Zitat Peters MJ et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592 PubMedCrossRef Peters MJ et al (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592 PubMedCrossRef
128.
Zurück zum Zitat Haroon NN et al (2015) Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 163(6):409–416 PubMedCrossRef Haroon NN et al (2015) Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 163(6):409–416 PubMedCrossRef
129.
Zurück zum Zitat Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19(4):358–362 PubMedCrossRef Heeneman S, Daemen MJ (2007) Cardiovascular risks in spondyloarthritides. Curr Opin Rheumatol 19(4):358–362 PubMedCrossRef
130.
Zurück zum Zitat Arida A et al (2015) Subclinical atherosclerosis is not accelerated in patients with Ankylosing Spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol 42(11):2098–2105 PubMedCrossRef Arida A et al (2015) Subclinical atherosclerosis is not accelerated in patients with Ankylosing Spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol 42(11):2098–2105 PubMedCrossRef
131.
Zurück zum Zitat Chen Y et al (2015) Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial spondyloarthritis. Rheumatol (oxford) 54(2):292–301 CrossRef Chen Y et al (2015) Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial spondyloarthritis. Rheumatol (oxford) 54(2):292–301 CrossRef
132.
Zurück zum Zitat Choe JY et al (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75(5):548–553 PubMedCrossRef Choe JY et al (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75(5):548–553 PubMedCrossRef
133.
Zurück zum Zitat Gonzalez-Juanatey C et al (2009) The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 88(6):358–365 CrossRef Gonzalez-Juanatey C et al (2009) The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 88(6):358–365 CrossRef
134.
Zurück zum Zitat Peters MJ et al (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166 PubMedCrossRef Peters MJ et al (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166 PubMedCrossRef
135.
Zurück zum Zitat Bengtsson K et al (2017) Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther 19(1):102 PubMedPubMedCentralCrossRef Bengtsson K et al (2017) Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther 19(1):102 PubMedPubMedCentralCrossRef
136.
Zurück zum Zitat Peters MJ et al (2010) Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 69(3):579–581 PubMedCrossRef Peters MJ et al (2010) Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 69(3):579–581 PubMedCrossRef
137.
Zurück zum Zitat Mathieu S et al (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (hoboken) 63(4):557–563 CrossRef Mathieu S et al (2011) Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (hoboken) 63(4):557–563 CrossRef
138.
Zurück zum Zitat van Halm VP et al (2006) Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65(11):1473–1477 PubMedPubMedCentralCrossRef van Halm VP et al (2006) Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis. Ann Rheum Dis 65(11):1473–1477 PubMedPubMedCentralCrossRef
139.
Zurück zum Zitat Berg IJ et al (2015) Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. J Rheumatol 42(4):645–653 PubMedCrossRef Berg IJ et al (2015) Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. J Rheumatol 42(4):645–653 PubMedCrossRef
140.
Zurück zum Zitat Spanakis E et al (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33(12):2440–2446 PubMed Spanakis E et al (2006) Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 33(12):2440–2446 PubMed
141.
Zurück zum Zitat van Eijk IC et al (2009) Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 60(5):1324–1330 PubMedCrossRef van Eijk IC et al (2009) Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis. Arthritis Rheum 60(5):1324–1330 PubMedCrossRef
142.
Zurück zum Zitat van Eijk IC et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 68(3):362–366 PubMedCrossRef van Eijk IC et al (2009) Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis 68(3):362–366 PubMedCrossRef
143.
Zurück zum Zitat Peters MJ et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331 PubMedCrossRef Peters MJ et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331 PubMedCrossRef
144.
Zurück zum Zitat Bianchi WA et al (2014) Assessment of fatigue in a large series of 1492 Brazilian patients with Spondyloarthritis. Mod Rheumatol 24(6):980–984 PubMedCrossRef Bianchi WA et al (2014) Assessment of fatigue in a large series of 1492 Brazilian patients with Spondyloarthritis. Mod Rheumatol 24(6):980–984 PubMedCrossRef
145.
Zurück zum Zitat Alkan BM et al (2013) Fatigue and correlation with disease-specific variables, spinal mobility measures, and health-related quality of life in ankylosing spondylitis. Mod Rheumatol 23(6):1101–1107 PubMedCrossRef Alkan BM et al (2013) Fatigue and correlation with disease-specific variables, spinal mobility measures, and health-related quality of life in ankylosing spondylitis. Mod Rheumatol 23(6):1101–1107 PubMedCrossRef
146.
Zurück zum Zitat van Tubergen A et al (2002) Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 47(1):8–16 PubMedCrossRef van Tubergen A et al (2002) Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 47(1):8–16 PubMedCrossRef
147.
Zurück zum Zitat Jones SD et al (1996) Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol 23(3):487–490 PubMed Jones SD et al (1996) Fatigue in ankylosing spondylitis: its prevalence and relationship to disease activity, sleep, and other factors. J Rheumatol 23(3):487–490 PubMed
148.
Zurück zum Zitat Bedaiwi M et al (2015) Fatigue in Ankylosing Spondylitis and Nonradiographic axial Spondyloarthritis: analysis from a longitudinal observation cohort. J Rheumatol 42(12):2354–2360 PubMedCrossRef Bedaiwi M et al (2015) Fatigue in Ankylosing Spondylitis and Nonradiographic axial Spondyloarthritis: analysis from a longitudinal observation cohort. J Rheumatol 42(12):2354–2360 PubMedCrossRef
149.
Zurück zum Zitat Dagfinrud H et al (2005) Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 53(1):5–11 PubMedCrossRef Dagfinrud H et al (2005) Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 53(1):5–11 PubMedCrossRef
150.
Zurück zum Zitat Chauffier K et al (2013) Fatigue in spondyloarthritis: a marker of disease activity. A cross-sectional study of 266 patients. Clin Exp Rheumatol 31(6):864–870 PubMed Chauffier K et al (2013) Fatigue in spondyloarthritis: a marker of disease activity. A cross-sectional study of 266 patients. Clin Exp Rheumatol 31(6):864–870 PubMed
151.
Zurück zum Zitat Gossec L et al (2016) Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort. Joint Bone Spine 83(4):427–431 PubMedCrossRef Gossec L et al (2016) Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort. Joint Bone Spine 83(4):427–431 PubMedCrossRef
152.
Zurück zum Zitat van der Heijde DM et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124 PubMedPubMedCentralCrossRef van der Heijde DM et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124 PubMedPubMedCentralCrossRef
153.
Zurück zum Zitat Revicki DA et al (2008) Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 35(7):1346–1353 PubMed Revicki DA et al (2008) Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 35(7):1346–1353 PubMed
154.
Zurück zum Zitat Espahbodi S et al (2017) Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clin Exp Rheumatol 35(4):571–578 PubMed Espahbodi S et al (2017) Fatigue contributes to work productivity impairment in patients with axial spondyloarthritis: a cross-sectional UK study. Clin Exp Rheumatol 35(4):571–578 PubMed
155.
Zurück zum Zitat Zochling J, Braun J (2009) Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4 Suppl 55):S127–30 PubMed Zochling J, Braun J (2009) Mortality in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 27(4 Suppl 55):S127–30 PubMed
156.
157.
Zurück zum Zitat Exarchou S et al (2016) Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 75(8):1466–1472 PubMedCrossRef Exarchou S et al (2016) Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis 75(8):1466–1472 PubMedCrossRef
158.
Zurück zum Zitat Oza A et al (2017) Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis 76(10):1737–1742 PubMedCrossRef Oza A et al (2017) Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study. Ann Rheum Dis 76(10):1737–1742 PubMedCrossRef
159.
Zurück zum Zitat Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921–1925 PubMedCrossRef Bakland G, Gran JT, Nossent JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921–1925 PubMedCrossRef
160.
Zurück zum Zitat Zink A, Minden K (2010) Entzündlich rheumatische Erkrankungen. Gesundheitsberichterstattung des Bundes, Bd. 49. R.-K.I., Berlin Zink A, Minden K (2010) Entzündlich rheumatische Erkrankungen. Gesundheitsberichterstattung des Bundes, Bd. 49. R.-K.I., Berlin
161.
Zurück zum Zitat Wysham KD et al (2017) Cervical spinal fracture and other diagnoses associated with mortality in hospitalized Ankylosing Spondylitis patients. Arthritis Care Res (hoboken) 69(2):271–277 CrossRef Wysham KD et al (2017) Cervical spinal fracture and other diagnoses associated with mortality in hospitalized Ankylosing Spondylitis patients. Arthritis Care Res (hoboken) 69(2):271–277 CrossRef
162.
Zurück zum Zitat Wick RR et al (2008) Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. Rheumatol (oxford) 47(6):855–859 CrossRef Wick RR et al (2008) Increased risk of myeloid leukaemia in patients with ankylosing spondylitis following treatment with radium-224. Rheumatol (oxford) 47(6):855–859 CrossRef
163.
Zurück zum Zitat Rudwaleit M et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31 PubMedCrossRef Rudwaleit M et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31 PubMedCrossRef
164.
Zurück zum Zitat Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 57(2):85–89 PubMed Amor B, Dougados M, Mijiyawa M (1990) Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 57(2):85–89 PubMed
165.
Zurück zum Zitat Dougados M et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34(10):1218–1227 PubMedCrossRef Dougados M et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34(10):1218–1227 PubMedCrossRef
167.
Zurück zum Zitat Aydin SZ et al (2012) Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. Ann Rheum Dis 71(1):56–60 PubMedCrossRef Aydin SZ et al (2012) Validation of the ASAS criteria and definition of a positive MRI of the sacroiliac joint in an inception cohort of axial spondyloarthritis followed up for 8 years. Ann Rheum Dis 71(1):56–60 PubMedCrossRef
168.
Zurück zum Zitat Sepriano A et al (2016) Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Ann Rheum Dis 75(6):1034–1042 PubMedCrossRef Sepriano A et al (2016) Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Ann Rheum Dis 75(6):1034–1042 PubMedCrossRef
169.
Zurück zum Zitat Molto A et al (2013) Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study. Arthritis Care Res (hoboken) 65(9):1472–1481 CrossRef Molto A et al (2013) Performances of the Assessment of SpondyloArthritis International Society axial spondyloarthritis criteria for diagnostic and classification purposes in patients visiting a rheumatologist because of chronic back pain: results from a multicenter, cross-sectional study. Arthritis Care Res (hoboken) 65(9):1472–1481 CrossRef
170.
Zurück zum Zitat Molto A et al (2014) Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. Ann Rheum Dis 74(4):746–751 PubMedCrossRef Molto A et al (2014) Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort. Ann Rheum Dis 74(4):746–751 PubMedCrossRef
172.
Zurück zum Zitat Ez-Zaitouni Z et al (2017) Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis 76(6):1086–1092 PubMedCrossRef Ez-Zaitouni Z et al (2017) Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis 76(6):1086–1092 PubMedCrossRef
173.
Zurück zum Zitat Bakker PA et al (2016) Are additional tests needed to rule out axial Spondyloarthritis in patients ages 16–45 years with short-duration chronic back pain and maximally one Spondyloarthritis feature? Arthritis Care Res (hoboken) 68(11):1726–1730 CrossRef Bakker PA et al (2016) Are additional tests needed to rule out axial Spondyloarthritis in patients ages 16–45 years with short-duration chronic back pain and maximally one Spondyloarthritis feature? Arthritis Care Res (hoboken) 68(11):1726–1730 CrossRef
174.
Zurück zum Zitat Joven BE et al (2017) Diagnostic value and validity of early Spondyloarthritis features: results from a national Spanish cohort. Arthritis Care Res (hoboken) 69(6):938–942 CrossRef Joven BE et al (2017) Diagnostic value and validity of early Spondyloarthritis features: results from a national Spanish cohort. Arthritis Care Res (hoboken) 69(6):938–942 CrossRef
175.
Zurück zum Zitat van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368 PubMedCrossRef van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368 PubMedCrossRef
176.
Zurück zum Zitat Wallman JK et al (2015) Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients—baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Res Ther 17(1):378 PubMedPubMedCentralCrossRef Wallman JK et al (2015) Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients—baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice. Arthritis Res Ther 17(1):378 PubMedPubMedCentralCrossRef
177.
Zurück zum Zitat Malaviya AN et al (2015) Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi. Int J Rheum Dis 18(7):736–741 PubMedCrossRef Malaviya AN et al (2015) Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi. Int J Rheum Dis 18(7):736–741 PubMedCrossRef
178.
Zurück zum Zitat Glintborg B et al (2017) Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry. J Rheumatol 44(1):59–69 PubMedCrossRef Glintborg B et al (2017) Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry. J Rheumatol 44(1):59–69 PubMedCrossRef
179.
Zurück zum Zitat Sieper J, Rudwaleit M (2005) Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 64(5):659–663 PubMedCrossRef Sieper J, Rudwaleit M (2005) Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 64(5):659–663 PubMedCrossRef
180.
Zurück zum Zitat Heuft-Dorenbosch L et al (2007) Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis 66(1):92–98 PubMedCrossRef Heuft-Dorenbosch L et al (2007) Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. Ann Rheum Dis 66(1):92–98 PubMedCrossRef
181.
Zurück zum Zitat Dean LE, Macfarlane GJ, Jones GT (2016) Differences in the prevalence of ankylosing spondylitis in primary and secondary care: only one-third of patients are managed in rheumatology. Rheumatol (oxford) 55(10):1820–1825 CrossRef Dean LE, Macfarlane GJ, Jones GT (2016) Differences in the prevalence of ankylosing spondylitis in primary and secondary care: only one-third of patients are managed in rheumatology. Rheumatol (oxford) 55(10):1820–1825 CrossRef
182.
Zurück zum Zitat Deodhar A et al (2016) Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol 35(7):1769–1776 PubMedPubMedCentralCrossRef Deodhar A et al (2016) Ankylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delay. Clin Rheumatol 35(7):1769–1776 PubMedPubMedCentralCrossRef
183.
Zurück zum Zitat Underwood MR, Dawes P (1995) Inflammatory back pain in primary care. Br J Rheumatol 34(11):1074–1077 PubMedCrossRef Underwood MR, Dawes P (1995) Inflammatory back pain in primary care. Br J Rheumatol 34(11):1074–1077 PubMedCrossRef
184.
Zurück zum Zitat Strand V et al (2013) Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (hoboken) 65(8):1299–1306 CrossRef Strand V et al (2013) Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res (hoboken) 65(8):1299–1306 CrossRef
185.
Zurück zum Zitat Liao ZT et al (2009) An epidemiological survey of low back pain and axial spondyloarthritis in a Chinese Han population. Scand J Rheumatol 38(6):455–459 PubMedCrossRef Liao ZT et al (2009) An epidemiological survey of low back pain and axial spondyloarthritis in a Chinese Han population. Scand J Rheumatol 38(6):455–459 PubMedCrossRef
186.
Zurück zum Zitat Weisman MH, Witter JP, Reveille JD (2013) The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10. Ann Rheum Dis 72(3):369–373 PubMedCrossRef Weisman MH, Witter JP, Reveille JD (2013) The prevalence of inflammatory back pain: population-based estimates from the US National Health and Nutrition Examination Survey, 2009–10. Ann Rheum Dis 72(3):369–373 PubMedCrossRef
187.
Zurück zum Zitat Jois RN, Macgregor AJ, Gaffney K (2008) Recognition of inflammatory back pain and ankylosing spondylitis in primary care. Rheumatol (oxford) 47(9):1364–1366 CrossRef Jois RN, Macgregor AJ, Gaffney K (2008) Recognition of inflammatory back pain and ankylosing spondylitis in primary care. Rheumatol (oxford) 47(9):1364–1366 CrossRef
188.
Zurück zum Zitat Brandt HC et al (2007) Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 66(11):1479–1484 PubMedPubMedCentralCrossRef Brandt HC et al (2007) Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 66(11):1479–1484 PubMedPubMedCentralCrossRef
189.
Zurück zum Zitat Hermann J et al (2009) Early spondyloarthritis: usefulness of clinical screening. Rheumatol (oxford) 48(7):812–816 CrossRef Hermann J et al (2009) Early spondyloarthritis: usefulness of clinical screening. Rheumatol (oxford) 48(7):812–816 CrossRef
190.
Zurück zum Zitat Braun A et al (2011) Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? Ann Rheum Dis 70(10):1782–1787 PubMedCrossRef Braun A et al (2011) Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? Ann Rheum Dis 70(10):1782–1787 PubMedCrossRef
191.
Zurück zum Zitat Poddubnyy D et al (2011) Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol 38(11):2452–2460 PubMedCrossRef Poddubnyy D et al (2011) Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. J Rheumatol 38(11):2452–2460 PubMedCrossRef
192.
Zurück zum Zitat Sampaio-Barros PD et al (2010) Undifferentiated spondyloarthritis: a longterm followup. J Rheumatol 37(6):1195–1199 PubMedCrossRef Sampaio-Barros PD et al (2010) Undifferentiated spondyloarthritis: a longterm followup. J Rheumatol 37(6):1195–1199 PubMedCrossRef
193.
Zurück zum Zitat Freeston J et al (2007) Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. Joint Bone Spine 74(2):140–143 PubMedCrossRef Freeston J et al (2007) Ankylosing spondylitis, HLA-B27 positivity and the need for biologic therapies. Joint Bone Spine 74(2):140–143 PubMedCrossRef
194.
Zurück zum Zitat Chung HY et al (2011) HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis 70(11):1930–1936 PubMedCrossRef Chung HY et al (2011) HLA-B27 positive patients differ from HLA-B27 negative patients in clinical presentation and imaging: results from the DESIR cohort of patients with recent onset axial spondyloarthritis. Ann Rheum Dis 70(11):1930–1936 PubMedCrossRef
195.
Zurück zum Zitat van Onna M et al (2011) HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. Ann Rheum Dis 70(11):1981–1985 PubMedCrossRef van Onna M et al (2011) HLA-B27 and gender independently determine the likelihood of a positive MRI of the sacroiliac joints in patients with early inflammatory back pain: a 2-year MRI follow-up study. Ann Rheum Dis 70(11):1981–1985 PubMedCrossRef
196.
Zurück zum Zitat Linssen A (1990) B27+ disease versus B27− disease. Scand J Rheumatol Suppl 87:111–118 (discussion 118–9) PubMedCrossRef Linssen A (1990) B27+ disease versus B27− disease. Scand J Rheumatol Suppl 87:111–118 (discussion 118–9) PubMedCrossRef
197.
Zurück zum Zitat Khan MA, Kushner I, Braun WE (1977) Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 20(4):909–912 PubMedCrossRef Khan MA, Kushner I, Braun WE (1977) Comparison of clinical features in HLA-B27 positive and negative patients with ankylosing spondylitis. Arthritis Rheum 20(4):909–912 PubMedCrossRef
198.
Zurück zum Zitat Kim TJ et al (2009) HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. Clin Exp Rheumatol 27(4):574–579 PubMed Kim TJ et al (2009) HLA-B27 homozygosity has no influence on clinical manifestations and functional disability in ankylosing spondylitis. Clin Exp Rheumatol 27(4):574–579 PubMed
199.
Zurück zum Zitat Lin H, Gong YZ (2017) Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis. Rheumatol Int 37(8):1267–1280 PubMedCrossRef Lin H, Gong YZ (2017) Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis. Rheumatol Int 37(8):1267–1280 PubMedCrossRef
200.
Zurück zum Zitat Spoorenberg A et al (1999) Relative value of erythrocyte sedimentation rate and C‑reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984 PubMed Spoorenberg A et al (1999) Relative value of erythrocyte sedimentation rate and C‑reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26(4):980–984 PubMed
201.
Zurück zum Zitat Braun A et al (2013) Optimizing the identification of patients with axial spondyloarthritis in primary care—the case for a two-step strategy combining the most relevant clinical items with HLA B27. Rheumatol (oxford) 52(8):1418–1424 CrossRef Braun A et al (2013) Optimizing the identification of patients with axial spondyloarthritis in primary care—the case for a two-step strategy combining the most relevant clinical items with HLA B27. Rheumatol (oxford) 52(8):1418–1424 CrossRef
202.
Zurück zum Zitat van Hoeven L et al (2014) Identifying axial spondyloarthritis in Dutch primary care patients, ages 20–45 years, with chronic low back pain. Arthritis Care Res (hoboken) 66(3):446–453 CrossRef van Hoeven L et al (2014) Identifying axial spondyloarthritis in Dutch primary care patients, ages 20–45 years, with chronic low back pain. Arthritis Care Res (hoboken) 66(3):446–453 CrossRef
203.
Zurück zum Zitat Sieper J et al (2013) Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis 72(10):1621–1627 PubMedCrossRef Sieper J et al (2013) Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study. Ann Rheum Dis 72(10):1621–1627 PubMedCrossRef
204.
Zurück zum Zitat Abawi O et al (2017) Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort. RMD Open 3(1):e389 PubMedPubMedCentralCrossRef Abawi O et al (2017) Evaluation of multiple referral strategies for axial spondyloarthritis in the SPondyloArthritis Caught Early (SPACE) cohort. RMD Open 3(1):e389 PubMedPubMedCentralCrossRef
205.
Zurück zum Zitat Baraliakos X et al (2008) The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 10(5):R104 PubMedPubMedCentralCrossRef Baraliakos X et al (2008) The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 10(5):R104 PubMedPubMedCentralCrossRef
206.
Zurück zum Zitat Maksymowych WP et al (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60(1):93–102 PubMedCrossRef Maksymowych WP et al (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60(1):93–102 PubMedCrossRef
207.
Zurück zum Zitat Chiowchanwisawakit P et al (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225 PubMedCrossRef Chiowchanwisawakit P et al (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225 PubMedCrossRef
208.
Zurück zum Zitat Pedersen SJ et al (2011) Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor alpha inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 63(12):3789–3800 PubMedCrossRef Pedersen SJ et al (2011) Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor alpha inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 63(12):3789–3800 PubMedCrossRef
209.
Zurück zum Zitat Pedersen SJ et al (2011) Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 38(7):1349–1354 PubMedCrossRef Pedersen SJ et al (2011) Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 38(7):1349–1354 PubMedCrossRef
210.
Zurück zum Zitat Baraliakos X et al (2007) Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 66(7):910–915 PubMedPubMedCentralCrossRef Baraliakos X et al (2007) Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 66(7):910–915 PubMedPubMedCentralCrossRef
211.
Zurück zum Zitat Diarra D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156–163 PubMedCrossRef Diarra D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156–163 PubMedCrossRef
212.
Zurück zum Zitat Daoussis D et al (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62(1):150–158 PubMedCrossRef Daoussis D et al (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62(1):150–158 PubMedCrossRef
213.
Zurück zum Zitat Appel H et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60(11):3257–3262 PubMedCrossRef Appel H et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60(11):3257–3262 PubMedCrossRef
214.
Zurück zum Zitat Mau W et al (1988) Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 15(7):1109–1114 PubMed Mau W et al (1988) Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 15(7):1109–1114 PubMed
215.
Zurück zum Zitat Poddubnyy D et al (2011) Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 70(8):1369–1374 PubMedCrossRef Poddubnyy D et al (2011) Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 70(8):1369–1374 PubMedCrossRef
216.
Zurück zum Zitat Dougados M et al (2017) Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5‑year data of the DESIR cohort. Ann Rheum Dis 76(11):1823–1828 PubMedCrossRef Dougados M et al (2017) Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5‑year data of the DESIR cohort. Ann Rheum Dis 76(11):1823–1828 PubMedCrossRef
217.
Zurück zum Zitat Wang R, Gabriel SE, Ward MM (2016) Progression of Nonradiographic axial Spondyloarthritis to Ankylosing Spondylitis: a population-based cohort study. Arthritis Rheumatol 68(6):1415–1421 PubMedPubMedCentralCrossRef Wang R, Gabriel SE, Ward MM (2016) Progression of Nonradiographic axial Spondyloarthritis to Ankylosing Spondylitis: a population-based cohort study. Arthritis Rheumatol 68(6):1415–1421 PubMedPubMedCentralCrossRef
218.
Zurück zum Zitat Baraliakos X et al (2009) Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 61(6):764–771 PubMedCrossRef Baraliakos X et al (2009) Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 61(6):764–771 PubMedCrossRef
219.
Zurück zum Zitat Lee JS et al (2015) Relationship between cervical sagittal alignment and quality of life in ankylosing spondylitis. Eur Spine J 24(6):1199–1203 PubMedCrossRef Lee JS et al (2015) Relationship between cervical sagittal alignment and quality of life in ankylosing spondylitis. Eur Spine J 24(6):1199–1203 PubMedCrossRef
220.
Zurück zum Zitat Baraliakos X et al (2011) The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. Curr Rheumatol Rep 13(5):383–387 PubMedCrossRef Baraliakos X et al (2011) The natural course of radiographic progression in ankylosing spondylitis: differences between genders and appearance of characteristic radiographic features. Curr Rheumatol Rep 13(5):383–387 PubMedCrossRef
221.
Zurück zum Zitat Poddubnyy D et al (2016) High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 75(12):2114–2118 PubMedCrossRef Poddubnyy D et al (2016) High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis 75(12):2114–2118 PubMedCrossRef
222.
Zurück zum Zitat van Tubergen A et al (2012) Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 71(4):518–523 PubMedCrossRef van Tubergen A et al (2012) Development of new syndesmophytes and bridges in ankylosing spondylitis and their predictors: a longitudinal study. Ann Rheum Dis 71(4):518–523 PubMedCrossRef
223.
Zurück zum Zitat Ramiro S et al (2014) Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 73(8):1455–1461 PubMedCrossRef Ramiro S et al (2014) Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis 73(8):1455–1461 PubMedCrossRef
224.
Zurück zum Zitat Poddubnyy D et al (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64(5):1388–1398 PubMedCrossRef Poddubnyy D et al (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64(5):1388–1398 PubMedCrossRef
225.
Zurück zum Zitat van der Heijde D et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063–3070 PubMedCrossRef van der Heijde D et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063–3070 PubMedCrossRef
226.
Zurück zum Zitat MacKay K et al (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 41(12):2263–2270 PubMedCrossRef MacKay K et al (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum 41(12):2263–2270 PubMedCrossRef
227.
Zurück zum Zitat Averns HL et al (1996) Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 35(4):373–376 PubMedCrossRef Averns HL et al (1996) Radiological outcome in ankylosing spondylitis: use of the Stoke Ankylosing Spondylitis Spine Score (SASSS). Br J Rheumatol 35(4):373–376 PubMedCrossRef
228.
Zurück zum Zitat Creemers MC et al (2005) Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64(1):127–129 PubMedCrossRef Creemers MC et al (2005) Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 64(1):127–129 PubMedCrossRef
229.
Zurück zum Zitat Salaffi F et al (2007) Radiological scoring methods for ankylosing spondylitis: a comparison between the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score. Clin Exp Rheumatol 25(1):67–74 PubMed Salaffi F et al (2007) Radiological scoring methods for ankylosing spondylitis: a comparison between the Bath Ankylosing Spondylitis Radiology Index and the modified Stoke Ankylosing Spondylitis Spine Score. Clin Exp Rheumatol 25(1):67–74 PubMed
230.
Zurück zum Zitat de Bruin F et al (2016) Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16–45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatol (oxford) 55(1):56–65 CrossRef de Bruin F et al (2016) Prevalence of degenerative changes of the spine on magnetic resonance images and radiographs in patients aged 16–45 years with chronic back pain of short duration in the Spondyloarthritis Caught Early (SPACE) cohort. Rheumatol (oxford) 55(1):56–65 CrossRef
231.
Zurück zum Zitat Vosse D et al (2007) Comparing morphometric X‑ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatol (oxford) 46(11):1667–1671 CrossRef Vosse D et al (2007) Comparing morphometric X‑ray absorptiometry and radiography in defining vertebral wedge fractures in patients with ankylosing spondylitis. Rheumatol (oxford) 46(11):1667–1671 CrossRef
232.
Zurück zum Zitat Diekhoff T et al (2017) Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Ann Rheum Dis 76(9):1502–1508 PubMedCrossRef Diekhoff T et al (2017) Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Ann Rheum Dis 76(9):1502–1508 PubMedCrossRef
233.
Zurück zum Zitat Baraliakos X et al (2005) Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 64(8):1141–1144 PubMedPubMedCentralCrossRef Baraliakos X et al (2005) Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 64(8):1141–1144 PubMedPubMedCentralCrossRef
234.
Zurück zum Zitat Rudwaleit M et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527 PubMedCrossRef Rudwaleit M et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68(10):1520–1527 PubMedCrossRef
235.
Zurück zum Zitat Weber U et al (2009) Sensitivity and specificity of spinal inflammatory lesions assessed by whole-body magnetic resonance imaging in patients with ankylosing spondylitis or recent-onset inflammatory back pain. Arthritis Rheum 61(7):900–908 PubMedCrossRef Weber U et al (2009) Sensitivity and specificity of spinal inflammatory lesions assessed by whole-body magnetic resonance imaging in patients with ankylosing spondylitis or recent-onset inflammatory back pain. Arthritis Rheum 61(7):900–908 PubMedCrossRef
236.
Zurück zum Zitat Althoff CE et al (2013) Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis 72(6):967–973 PubMedCrossRef Althoff CE et al (2013) Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI. Ann Rheum Dis 72(6):967–973 PubMedCrossRef
237.
Zurück zum Zitat Weber U et al (2009) Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis. Arthritis Rheum 61(7):893–899 PubMedCrossRef Weber U et al (2009) Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis. Arthritis Rheum 61(7):893–899 PubMedCrossRef
238.
Zurück zum Zitat Weber U et al (2010) Assessment of active spinal inflammatory changes in patients with axial spondyloarthritis: validation of whole body MRI against conventional MRI. Ann Rheum Dis 69(4):648–653 PubMedCrossRef Weber U et al (2010) Assessment of active spinal inflammatory changes in patients with axial spondyloarthritis: validation of whole body MRI against conventional MRI. Ann Rheum Dis 69(4):648–653 PubMedCrossRef
239.
Zurück zum Zitat Bollow M et al (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59(2):135–140 PubMedPubMedCentralCrossRef Bollow M et al (2000) Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis—cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59(2):135–140 PubMedPubMedCentralCrossRef
240.
Zurück zum Zitat Gong Y et al (2012) Ten years’ experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum 64(5):1399–1406 PubMedCrossRef Gong Y et al (2012) Ten years’ experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum 64(5):1399–1406 PubMedCrossRef
241.
Zurück zum Zitat Muche B et al (2003) Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 48(5):1374–1384 PubMedCrossRef Muche B et al (2003) Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 48(5):1374–1384 PubMedCrossRef
242.
Zurück zum Zitat Madsen KB, Jurik AG (2010) Magnetic resonance imaging grading system for active and chronic spondylarthritis changes in the sacroiliac joint. Arthritis Care Res (hoboken) 62(1):11–18 CrossRef Madsen KB, Jurik AG (2010) Magnetic resonance imaging grading system for active and chronic spondylarthritis changes in the sacroiliac joint. Arthritis Care Res (hoboken) 62(1):11–18 CrossRef
243.
Zurück zum Zitat Madsen KB, Egund N, Jurik AG (2010) Grading of inflammatory disease activity in the sacroiliac joints with magnetic resonance imaging: comparison between short-tau inversion recovery and gadolinium contrast-enhanced sequences. J Rheumatol 37(2):393–400 PubMedCrossRef Madsen KB, Egund N, Jurik AG (2010) Grading of inflammatory disease activity in the sacroiliac joints with magnetic resonance imaging: comparison between short-tau inversion recovery and gadolinium contrast-enhanced sequences. J Rheumatol 37(2):393–400 PubMedCrossRef
244.
Zurück zum Zitat Marzo-Ortega H et al (2009) Baseline and 1‑year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 68(11):1721–1727 PubMedCrossRef Marzo-Ortega H et al (2009) Baseline and 1‑year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 68(11):1721–1727 PubMedCrossRef
245.
Zurück zum Zitat Song IH et al (2011) Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis 70(7):1257–1263 PubMedCrossRef Song IH et al (2011) Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. Ann Rheum Dis 70(7):1257–1263 PubMedCrossRef
246.
Zurück zum Zitat Hu Z et al (2016) Backfill is a specific sign of axial spondyloarthritis seen on MRI. Joint Bone Spine 83(2):179–183 PubMedCrossRef Hu Z et al (2016) Backfill is a specific sign of axial spondyloarthritis seen on MRI. Joint Bone Spine 83(2):179–183 PubMedCrossRef
247.
Zurück zum Zitat Wick MC et al (2010) Erosions are the most relevant magnetic resonance imaging features in quantification of sacroiliac joints in ankylosing spondylitis. J Rheumatol 37(3):622–627 PubMedCrossRef Wick MC et al (2010) Erosions are the most relevant magnetic resonance imaging features in quantification of sacroiliac joints in ankylosing spondylitis. J Rheumatol 37(3):622–627 PubMedCrossRef
248.
Zurück zum Zitat Weber U et al (2013) Development and validation of a magnetic resonance imaging reference criterion for defining a positive sacroiliac joint magnetic resonance imaging finding in spondyloarthritis. Arthritis Care Res (hoboken) 65(6):977–985 CrossRef Weber U et al (2013) Development and validation of a magnetic resonance imaging reference criterion for defining a positive sacroiliac joint magnetic resonance imaging finding in spondyloarthritis. Arthritis Care Res (hoboken) 65(6):977–985 CrossRef
249.
Zurück zum Zitat Weber U et al (2010) The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum 62(10):3048–3058 PubMedCrossRef Weber U et al (2010) The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum 62(10):3048–3058 PubMedCrossRef
250.
Zurück zum Zitat Weber U et al (2010) Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondylarthritis. Arthritis Care Res (hoboken) 62(12):1763–1771 CrossRef Weber U et al (2010) Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondylarthritis. Arthritis Care Res (hoboken) 62(12):1763–1771 CrossRef
251.
Zurück zum Zitat Madsen KB, Schiottz-Christensen B, Jurik AG (2010) Prognostic significance of magnetic resonance imaging changes of the sacroiliac joints in spondyloarthritis—a followup study. J Rheumatol 37(8):1718–1727 PubMedCrossRef Madsen KB, Schiottz-Christensen B, Jurik AG (2010) Prognostic significance of magnetic resonance imaging changes of the sacroiliac joints in spondyloarthritis—a followup study. J Rheumatol 37(8):1718–1727 PubMedCrossRef
252.
Zurück zum Zitat Bennett AN et al (2008) Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 58(11):3413–3418 PubMedCrossRef Bennett AN et al (2008) Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 58(11):3413–3418 PubMedCrossRef
253.
Zurück zum Zitat Pedersen SJ et al (2016) Course of magnetic resonance imaging-detected inflammation and structural lesions in the sacroiliac joints of patients in the randomized, double-blind, placebo-controlled Danish Multicenter study of Adalimumab in Spondyloarthritis, as assessed by the berlin and Spondyloarthritis research consortium of Canada methods. Arthritis Rheumatol 68(2):418–429 PubMedCrossRef Pedersen SJ et al (2016) Course of magnetic resonance imaging-detected inflammation and structural lesions in the sacroiliac joints of patients in the randomized, double-blind, placebo-controlled Danish Multicenter study of Adalimumab in Spondyloarthritis, as assessed by the berlin and Spondyloarthritis research consortium of Canada methods. Arthritis Rheumatol 68(2):418–429 PubMedCrossRef
254.
Zurück zum Zitat Baraliakos X et al (2005) Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 64(5):730–734 PubMedCrossRef Baraliakos X et al (2005) Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 64(5):730–734 PubMedCrossRef
255.
Zurück zum Zitat Rennie WJ et al (2009) Magnetic resonance imaging assessment of spinal inflammation in ankylosing spondylitis: standard clinical protocols may omit inflammatory lesions in thoracic vertebrae. Arthritis Rheum 61(9):1187–1193 PubMedCrossRef Rennie WJ et al (2009) Magnetic resonance imaging assessment of spinal inflammation in ankylosing spondylitis: standard clinical protocols may omit inflammatory lesions in thoracic vertebrae. Arthritis Rheum 61(9):1187–1193 PubMedCrossRef
256.
Zurück zum Zitat Appel H et al (2006) Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 8(5):R143 PubMedPubMedCentralCrossRef Appel H et al (2006) Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 8(5):R143 PubMedPubMedCentralCrossRef
257.
Zurück zum Zitat Jevtic V et al (2000) Marginal erosive discovertebral “Romanus” lesions in ankylosing spondylitis demonstrated by contrast enhanced Gd-DTPA magnetic resonance imaging. Skeletal Radiol 29(1):27–33 PubMedCrossRef Jevtic V et al (2000) Marginal erosive discovertebral “Romanus” lesions in ankylosing spondylitis demonstrated by contrast enhanced Gd-DTPA magnetic resonance imaging. Skeletal Radiol 29(1):27–33 PubMedCrossRef
258.
Zurück zum Zitat Romanus R, Yden S (1952) Destructive and ossifying spondylitic changes in rheumatoid ankylosing spondylitis (pelvo-spondylitis ossificans). Acta Orthop Scand 22(2):88–99 PubMedCrossRef Romanus R, Yden S (1952) Destructive and ossifying spondylitic changes in rheumatoid ankylosing spondylitis (pelvo-spondylitis ossificans). Acta Orthop Scand 22(2):88–99 PubMedCrossRef
259.
Zurück zum Zitat Bennett AN et al (2009) Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum 60(5):1331–1341 PubMedCrossRef Bennett AN et al (2009) Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum 60(5):1331–1341 PubMedCrossRef
260.
Zurück zum Zitat Kenny JB, Hughes PL, Whitehouse GH (1990) Discovertebral destruction in ankylosing spondylitis: the role of computed tomography and magnetic resonance imaging. Br J Radiol 63(750):448–455 PubMedCrossRef Kenny JB, Hughes PL, Whitehouse GH (1990) Discovertebral destruction in ankylosing spondylitis: the role of computed tomography and magnetic resonance imaging. Br J Radiol 63(750):448–455 PubMedCrossRef
261.
Zurück zum Zitat Kabasakal Y, Garrett SL, Calin A (1996) The epidemiology of spondylodiscitis in ankylosing spondylitis—a controlled study. Br J Rheumatol 35(7):660–663 PubMedCrossRef Kabasakal Y, Garrett SL, Calin A (1996) The epidemiology of spondylodiscitis in ankylosing spondylitis—a controlled study. Br J Rheumatol 35(7):660–663 PubMedCrossRef
262.
Zurück zum Zitat Bennett AN et al (2010) The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. Ann Rheum Dis 69(5):891–894 PubMedCrossRef Bennett AN et al (2010) The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy. Ann Rheum Dis 69(5):891–894 PubMedCrossRef
263.
Zurück zum Zitat Braun J et al (2004) Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 63(9):1046–1055 PubMedPubMedCentralCrossRef Braun J et al (2004) Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 63(9):1046–1055 PubMedPubMedCentralCrossRef
264.
Zurück zum Zitat Braun J et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136 PubMedCrossRef Braun J et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136 PubMedCrossRef
265.
Zurück zum Zitat van der Heijde D et al (2007) Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? J Rheumatol 34(4):871–873 PubMed van der Heijde D et al (2007) Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? J Rheumatol 34(4):871–873 PubMed
266.
Zurück zum Zitat Maksymowych WP et al (2005) Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 53(5):703–709 PubMedCrossRef Maksymowych WP et al (2005) Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 53(5):703–709 PubMedCrossRef
267.
Zurück zum Zitat Maksymowych WP et al (2007) Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? Arthritis Rheum 57(3):501–507 PubMedCrossRef Maksymowych WP et al (2007) Validation of the spondyloarthritis research consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? Arthritis Rheum 57(3):501–507 PubMedCrossRef
268.
Zurück zum Zitat Lukas C et al (2007) Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 34(4):862–870 PubMed Lukas C et al (2007) Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 34(4):862–870 PubMed
269.
Zurück zum Zitat Treitl M et al (2008) Magnetic resonance imaging assessment of spinal inflammation in patients treated for ankylosing spondylitis. J Rheumatol 35(1):126–136 PubMed Treitl M et al (2008) Magnetic resonance imaging assessment of spinal inflammation in patients treated for ankylosing spondylitis. J Rheumatol 35(1):126–136 PubMed
270.
Zurück zum Zitat Kiltz U et al (2012) The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 71(7):1207–1211 PubMedCrossRef Kiltz U et al (2012) The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 71(7):1207–1211 PubMedCrossRef
271.
Zurück zum Zitat Madsen KB, Jurik AG (2010) MRI grading method for active and chronic spinal changes in spondyloarthritis. Clin Radiol 65(1):6–14 PubMedCrossRef Madsen KB, Jurik AG (2010) MRI grading method for active and chronic spinal changes in spondyloarthritis. Clin Radiol 65(1):6–14 PubMedCrossRef
272.
Zurück zum Zitat Weber U et al (2015) Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis? Ann Rheum Dis 74(6):985–992 PubMedCrossRef Weber U et al (2015) Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis? Ann Rheum Dis 74(6):985–992 PubMedCrossRef
273.
Zurück zum Zitat Hermann KG et al (2012) Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis 71(8):1278–1288 PubMedCrossRef Hermann KG et al (2012) Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis 71(8):1278–1288 PubMedCrossRef
274.
Zurück zum Zitat Rudwaleit M et al (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281 PubMedCrossRef Rudwaleit M et al (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281 PubMedCrossRef
275.
Zurück zum Zitat Braun J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54(5):1646–1652 PubMedCrossRef Braun J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54(5):1646–1652 PubMedCrossRef
276.
Zurück zum Zitat Baraliakos X et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53(6):856–863 PubMedCrossRef Baraliakos X et al (2005) Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 53(6):856–863 PubMedCrossRef
277.
Zurück zum Zitat Baraliakos X et al (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223 PubMedCrossRef Baraliakos X et al (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223 PubMedCrossRef
278.
Zurück zum Zitat Sieper J et al (2005) Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatol (oxford) 44(12):1525–1530 CrossRef Sieper J et al (2005) Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatol (oxford) 44(12):1525–1530 CrossRef
279.
Zurück zum Zitat Jarrett SJ et al (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68(9):1466–1469 PubMedCrossRef Jarrett SJ et al (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68(9):1466–1469 PubMedCrossRef
280.
Zurück zum Zitat Feydy A et al (2012) Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls. Ann Rheum Dis 71(4):498–503 PubMedCrossRef Feydy A et al (2012) Comparative study of MRI and power Doppler ultrasonography of the heel in patients with spondyloarthritis with and without heel pain and in controls. Ann Rheum Dis 71(4):498–503 PubMedCrossRef
281.
Zurück zum Zitat Spadaro A et al (2009) Sonographic-detected joint effusion compared with physical examination in the assessment of sacroiliac joints in spondyloarthritis. Ann Rheum Dis 68(10):1559–1563 PubMedCrossRef Spadaro A et al (2009) Sonographic-detected joint effusion compared with physical examination in the assessment of sacroiliac joints in spondyloarthritis. Ann Rheum Dis 68(10):1559–1563 PubMedCrossRef
282.
Zurück zum Zitat Unlu E, Pamuk ON, Cakir N (2007) Color and duplex Doppler sonography to detect sacroiliitis and spinal inflammation in ankylosing spondylitis. Can this method reveal response to anti-tumor necrosis factor therapy? J Rheumatol 34(1):110–116 PubMed Unlu E, Pamuk ON, Cakir N (2007) Color and duplex Doppler sonography to detect sacroiliitis and spinal inflammation in ankylosing spondylitis. Can this method reveal response to anti-tumor necrosis factor therapy? J Rheumatol 34(1):110–116 PubMed
283.
Zurück zum Zitat Aydin SZ et al (2010) Validation of ultrasound imaging for Achilles entheseal fibrocartilage in bovines and description of changes in humans with spondyloarthritis. Ann Rheum Dis 69(12):2165–2168 PubMedCrossRef Aydin SZ et al (2010) Validation of ultrasound imaging for Achilles entheseal fibrocartilage in bovines and description of changes in humans with spondyloarthritis. Ann Rheum Dis 69(12):2165–2168 PubMedCrossRef
284.
Zurück zum Zitat D’Agostino MA et al (2011) How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis 70(8):1433–1440 PubMedCrossRef D’Agostino MA et al (2011) How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis 70(8):1433–1440 PubMedCrossRef
285.
Zurück zum Zitat de Miguel E et al (2011) Diagnostic accuracy of enthesis ultrasound in the diagnosis of early spondyloarthritis. Ann Rheum Dis 70(3):434–439 PubMedCrossRef de Miguel E et al (2011) Diagnostic accuracy of enthesis ultrasound in the diagnosis of early spondyloarthritis. Ann Rheum Dis 70(3):434–439 PubMedCrossRef
286.
Zurück zum Zitat de Miguel E et al (2009) Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 68(2):169–174 PubMedCrossRef de Miguel E et al (2009) Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 68(2):169–174 PubMedCrossRef
287.
Zurück zum Zitat Ruyssen-Witrand A et al (2017) Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort. RMD Open 3(2):e482 PubMedPubMedCentralCrossRef Ruyssen-Witrand A et al (2017) Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort. RMD Open 3(2):e482 PubMedPubMedCentralCrossRef
288.
Zurück zum Zitat Song IH et al (2008) The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 67(11):1535–1540 PubMedCrossRef Song IH et al (2008) The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research. Ann Rheum Dis 67(11):1535–1540 PubMedCrossRef
289.
Zurück zum Zitat Song IH et al (2010) Limited diagnostic value of unilateral sacroiliitis in scintigraphy in assessing axial spondyloarthritis. J Rheumatol 37(6):1200–1202 PubMedCrossRef Song IH et al (2010) Limited diagnostic value of unilateral sacroiliitis in scintigraphy in assessing axial spondyloarthritis. J Rheumatol 37(6):1200–1202 PubMedCrossRef
290.
Zurück zum Zitat Devauchelle-Pensec V et al (2012) Computed tomography scanning facilitates the diagnosis of sacroiliitis in patients with suspected spondylarthritis: results of a prospective multicenter French cohort study. Arthritis Rheum 64(5):1412–1419 PubMedCrossRef Devauchelle-Pensec V et al (2012) Computed tomography scanning facilitates the diagnosis of sacroiliitis in patients with suspected spondylarthritis: results of a prospective multicenter French cohort study. Arthritis Rheum 64(5):1412–1419 PubMedCrossRef
291.
Zurück zum Zitat Strobel K et al (2010) 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging 37(9):1760–1765 PubMedCrossRef Strobel K et al (2010) 18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging 37(9):1760–1765 PubMedCrossRef
292.
Zurück zum Zitat Dougados M et al (1999) Clinical relevance of C‑reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 26(4):971–974 PubMed Dougados M et al (1999) Clinical relevance of C‑reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol 26(4):971–974 PubMed
293.
Zurück zum Zitat Benhamou M, Gossec L, Dougados M (2010) Clinical relevance of C‑reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C‑reactive protein. Rheumatol (oxford) 49(3):536–541 CrossRef Benhamou M, Gossec L, Dougados M (2010) Clinical relevance of C‑reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C‑reactive protein. Rheumatol (oxford) 49(3):536–541 CrossRef
294.
Zurück zum Zitat Kroon F et al (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623–1629 PubMedCrossRef Kroon F et al (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623–1629 PubMedCrossRef
295.
Zurück zum Zitat Poddubnyy D et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71(10):1616–1622 PubMedCrossRef Poddubnyy D et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71(10):1616–1622 PubMedCrossRef
296.
Zurück zum Zitat Poddubnyy DA et al (2010) Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69(7):1338–1341 PubMedCrossRef Poddubnyy DA et al (2010) Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69(7):1338–1341 PubMedCrossRef
297.
Zurück zum Zitat de Vries MK et al (2009) Erythrocyte sedimentation rate, C‑reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61(11):1484–1490 PubMedCrossRef de Vries MK et al (2009) Erythrocyte sedimentation rate, C‑reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61(11):1484–1490 PubMedCrossRef
298.
Zurück zum Zitat Klingberg E et al (2017) A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 19(1):21 PubMedPubMedCentralCrossRef Klingberg E et al (2017) A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther 19(1):21 PubMedPubMedCentralCrossRef
299.
Zurück zum Zitat Cypers H et al (2016) Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 75(7):1357–1362 PubMedCrossRef Cypers H et al (2016) Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 75(7):1357–1362 PubMedCrossRef
300.
Zurück zum Zitat van der Heijde D et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818 PubMedCrossRef van der Heijde D et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68(12):1811–1818 PubMedCrossRef
301.
Zurück zum Zitat Brandt J et al (2003) Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 62(3):264–273 PubMed Brandt J et al (2003) Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 62(3):264–273 PubMed
302.
Zurück zum Zitat Pavy S, Brophy S, Calin A (2005) Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 32(1):80–85 PubMed Pavy S, Brophy S, Calin A (2005) Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 32(1):80–85 PubMed
303.
Zurück zum Zitat Brandt J et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346–1352 PubMedCrossRef Brandt J et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346–1352 PubMedCrossRef
304.
Zurück zum Zitat Berthelot JM et al (2008) High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies? Joint Bone Spine 75(2):167–171 PubMedCrossRef Berthelot JM et al (2008) High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies? Joint Bone Spine 75(2):167–171 PubMedCrossRef
305.
Zurück zum Zitat Song IH et al (2009) Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 68(11):1701–1707 PubMedCrossRef Song IH et al (2009) Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis 68(11):1701–1707 PubMedCrossRef
306.
Zurück zum Zitat Machado P et al (2015) Calculating the ankylosing spondylitis disease activity score if the conventional c‑reactive protein level is below the limit of detection or if high-sensitivity c‑reactive protein is used: an analysis in the DESIR cohort. Arthritis Rheumatol 67(2):408–413 PubMedCrossRef Machado P et al (2015) Calculating the ankylosing spondylitis disease activity score if the conventional c‑reactive protein level is below the limit of detection or if high-sensitivity c‑reactive protein is used: an analysis in the DESIR cohort. Arthritis Rheumatol 67(2):408–413 PubMedCrossRef
307.
Zurück zum Zitat Machado P et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47–53 PubMedCrossRef Machado P et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47–53 PubMedCrossRef
308.
Zurück zum Zitat Nas K et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13(3):240–245 PubMedCrossRef Nas K et al (2010) Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis 13(3):240–245 PubMedCrossRef
309.
Zurück zum Zitat Pedersen SJ et al (2010) Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69(6):1065–1071 PubMedCrossRef Pedersen SJ et al (2010) Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 69(6):1065–1071 PubMedCrossRef
310.
Zurück zum Zitat Aydin SZ et al (2010) Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28(5):752–755 PubMed Aydin SZ et al (2010) Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol 28(5):752–755 PubMed
311.
Zurück zum Zitat Vastesaeger N et al (2014) ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin 10(4):204–209 PubMedCrossRef Vastesaeger N et al (2014) ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. Reumatol Clin 10(4):204–209 PubMedCrossRef
312.
Zurück zum Zitat Kilic E et al (2015) Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int 35(6):981–989 PubMedCrossRef Kilic E et al (2015) Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int 35(6):981–989 PubMedCrossRef
313.
Zurück zum Zitat Kilic G, Kilic E, Ozgocmen S (2017) Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis? Int J Rheum Dis 20(9):1201–1211 PubMedCrossRef Kilic G, Kilic E, Ozgocmen S (2017) Is there any gender-specific difference in the cut-off values of ankylosing spondylitis disease activity score in patients with axial spondyloarthritis? Int J Rheum Dis 20(9):1201–1211 PubMedCrossRef
314.
Zurück zum Zitat Huscher D et al (2015) Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. RMD Open 1(1):e33 PubMedPubMedCentralCrossRef Huscher D et al (2015) Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012. RMD Open 1(1):e33 PubMedPubMedCentralCrossRef
315.
Zurück zum Zitat Doran MF et al (2003) Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 30(2):316–320 PubMed Doran MF et al (2003) Predictors of longterm outcome in ankylosing spondylitis. J Rheumatol 30(2):316–320 PubMed
316.
Zurück zum Zitat Amor B et al (1994) Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 21(10):1883–1887 PubMed Amor B et al (1994) Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol 21(10):1883–1887 PubMed
317.
Zurück zum Zitat Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36(7):766–771 PubMedCrossRef Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 36(7):766–771 PubMedCrossRef
318.
Zurück zum Zitat Averns HL et al (1996) Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 25(3):138–142 PubMedCrossRef Averns HL et al (1996) Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 25(3):138–142 PubMedCrossRef
319.
Zurück zum Zitat Ward MM (2002) Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 29(7):1420–1425 PubMed Ward MM (2002) Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 29(7):1420–1425 PubMed
320.
Zurück zum Zitat Brophy S et al (2002) The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 29(6):1236–1243 PubMed Brophy S et al (2002) The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 29(6):1236–1243 PubMed
321.
Zurück zum Zitat van der Heijde D et al (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24(11):2225–2229 PubMed van der Heijde D et al (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24(11):2225–2229 PubMed
322.
Zurück zum Zitat van der Heijde D et al (1999) Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 26(4):1003–1005 PubMed van der Heijde D et al (1999) Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol 26(4):1003–1005 PubMed
323.
Zurück zum Zitat Anderson JJ et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886 PubMedCrossRef Anderson JJ et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886 PubMedCrossRef
324.
Zurück zum Zitat Sieper J et al (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71(5):700–706 PubMedCrossRef Sieper J et al (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71(5):700–706 PubMedCrossRef
325.
Zurück zum Zitat Rudwaleit M et al (2010) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 12(3):R117 PubMedPubMedCentralCrossRef Rudwaleit M et al (2010) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 12(3):R117 PubMedPubMedCentralCrossRef
326.
Zurück zum Zitat Glintborg B et al (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002–2008 PubMedCrossRef Glintborg B et al (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002–2008 PubMedCrossRef
327.
Zurück zum Zitat Lord PA et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatol (oxford) 49(3):563–570 CrossRef Lord PA et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatol (oxford) 49(3):563–570 CrossRef
328.
Zurück zum Zitat Perrotta FM et al (2014) Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFalpha drugs. Reumatismo 66(3):208–214 PubMedCrossRef Perrotta FM et al (2014) Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFalpha drugs. Reumatismo 66(3):208–214 PubMedCrossRef
329.
Zurück zum Zitat Rausch Osthoff AK et al (2018) EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77(9):1251–1260 PubMedCrossRef Rausch Osthoff AK et al (2018) EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77(9):1251–1260 PubMedCrossRef
330.
Zurück zum Zitat Klemz BN et al (2016) The relevance of performing exercise test before starting supervised physical exercise in asymptomatic cardiovascular patients with rheumatic diseases. Rheumatol (oxford) 55(11):1978–1986 CrossRef Klemz BN et al (2016) The relevance of performing exercise test before starting supervised physical exercise in asymptomatic cardiovascular patients with rheumatic diseases. Rheumatol (oxford) 55(11):1978–1986 CrossRef
331.
Zurück zum Zitat Dagfinrud H, Kvien TK, Hagen KB (2008) Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008(1):CD2822 PubMedCentral Dagfinrud H, Kvien TK, Hagen KB (2008) Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008(1):CD2822 PubMedCentral
332.
Zurück zum Zitat van Tubergen A et al (2001) Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 45(5):430–438 PubMedCrossRef van Tubergen A et al (2001) Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 45(5):430–438 PubMedCrossRef
333.
Zurück zum Zitat Escalas C et al (2016) Evaluation of physiotherapy in a prospective cohort of early axial spondyloarthritis. Data from the DESIR cohort. Joint Bone Spine 83(2):185–190 PubMedCrossRef Escalas C et al (2016) Evaluation of physiotherapy in a prospective cohort of early axial spondyloarthritis. Data from the DESIR cohort. Joint Bone Spine 83(2):185–190 PubMedCrossRef
334.
Zurück zum Zitat Albrecht K, Huscher D (2017) Do we prescribe physical medicine sufficiently? Current data from the German Collaborative Arthritis Center. Akt Rheumatol 42:118–121 CrossRef Albrecht K, Huscher D (2017) Do we prescribe physical medicine sufficiently? Current data from the German Collaborative Arthritis Center. Akt Rheumatol 42:118–121 CrossRef
335.
Zurück zum Zitat Martins NA et al (2014) Exercise and ankylosing spondylitis with New York modified criteria: a systematic review of controlled trials with meta-analysis. Acta Reumatol Port 39(4):298–308 PubMed Martins NA et al (2014) Exercise and ankylosing spondylitis with New York modified criteria: a systematic review of controlled trials with meta-analysis. Acta Reumatol Port 39(4):298–308 PubMed
336.
Zurück zum Zitat Sharan D, Rajkumar JS (2017) Physiotherapy for Ankylosing Spondylitis: systematic review and a proposed rehabilitation protocol. Curr Rheumatol Rev 13(2):121–125 PubMedCrossRef Sharan D, Rajkumar JS (2017) Physiotherapy for Ankylosing Spondylitis: systematic review and a proposed rehabilitation protocol. Curr Rheumatol Rev 13(2):121–125 PubMedCrossRef
337.
Zurück zum Zitat Jennings F et al (2015) Effects of aerobic training in patients with Ankylosing Spondylitis. J Rheumatol 42(12):2347–2353 PubMedCrossRef Jennings F et al (2015) Effects of aerobic training in patients with Ankylosing Spondylitis. J Rheumatol 42(12):2347–2353 PubMedCrossRef
338.
Zurück zum Zitat Liang H et al (2015) Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis. Clin Rheumatol 34(10):1737–1744 PubMedCrossRef Liang H et al (2015) Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis. Clin Rheumatol 34(10):1737–1744 PubMedCrossRef
339.
Zurück zum Zitat Niedermann K et al (2013) Effect of cardiovascular training on fitness and perceived disease activity in people with ankylosing spondylitis. Arthritis Care Res (hoboken) 65(11):1844–1852 CrossRef Niedermann K et al (2013) Effect of cardiovascular training on fitness and perceived disease activity in people with ankylosing spondylitis. Arthritis Care Res (hoboken) 65(11):1844–1852 CrossRef
340.
Zurück zum Zitat Rosu MO et al (2014) Effects of Pilates, McKenzie and Heckscher training on disease activity, spinal motility and pulmonary function in patients with ankylosing spondylitis: a randomized controlled trial. Rheumatol Int 34(3):367–372 PubMedCrossRef Rosu MO et al (2014) Effects of Pilates, McKenzie and Heckscher training on disease activity, spinal motility and pulmonary function in patients with ankylosing spondylitis: a randomized controlled trial. Rheumatol Int 34(3):367–372 PubMedCrossRef
341.
Zurück zum Zitat Altan L et al (2012) Effect of Pilates training on people with ankylosing spondylitis. Rheumatol Int 32(7):2093–2099 PubMedCrossRef Altan L et al (2012) Effect of Pilates training on people with ankylosing spondylitis. Rheumatol Int 32(7):2093–2099 PubMedCrossRef
342.
Zurück zum Zitat Passalent LA et al (2010) Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol 37(4):835–841 PubMedCrossRef Passalent LA et al (2010) Exercise in ankylosing spondylitis: discrepancies between recommendations and reality. J Rheumatol 37(4):835–841 PubMedCrossRef
343.
Zurück zum Zitat Fongen C, Halvorsen S, Dagfinrud H (2013) High disease activity is related to low levels of physical activity in patients with ankylosing spondylitis. Clin Rheumatol 32(12):1719–1725 PubMedCrossRef Fongen C, Halvorsen S, Dagfinrud H (2013) High disease activity is related to low levels of physical activity in patients with ankylosing spondylitis. Clin Rheumatol 32(12):1719–1725 PubMedCrossRef
344.
Zurück zum Zitat Kjeken I et al (2013) A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. J Rehabil Med 45(3):260–267 PubMedCrossRef Kjeken I et al (2013) A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. J Rehabil Med 45(3):260–267 PubMedCrossRef
345.
Zurück zum Zitat Masiero S et al (2014) Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. Clin Rehabil 28(6):562–572 PubMedCrossRef Masiero S et al (2014) Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. Clin Rehabil 28(6):562–572 PubMedCrossRef
346.
Zurück zum Zitat Durmus D et al (2009) Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol Int 29(6):673–677 PubMedCrossRef Durmus D et al (2009) Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol Int 29(6):673–677 PubMedCrossRef
347.
Zurück zum Zitat Durmus D et al (2009) Effects of two exercise interventions on pulmonary functions in the patients with ankylosing spondylitis. Joint Bone Spine 76(2):150–155 PubMedCrossRef Durmus D et al (2009) Effects of two exercise interventions on pulmonary functions in the patients with ankylosing spondylitis. Joint Bone Spine 76(2):150–155 PubMedCrossRef
348.
Zurück zum Zitat Karapolat H et al (2009) Are swimming or aerobic exercise better than conventional exercise in ankylosing spondylitis patients? A randomized controlled study. Eur J Phys Rehabil Med 45(4):449–457 PubMed Karapolat H et al (2009) Are swimming or aerobic exercise better than conventional exercise in ankylosing spondylitis patients? A randomized controlled study. Eur J Phys Rehabil Med 45(4):449–457 PubMed
349.
Zurück zum Zitat Widberg K, Karimi H, Hafstrom I (2009) Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis—a randomized study. Clin Rehabil 23(7):599–608 PubMedCrossRef Widberg K, Karimi H, Hafstrom I (2009) Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis—a randomized study. Clin Rehabil 23(7):599–608 PubMedCrossRef
350.
Zurück zum Zitat Aytekin E et al (2012) Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions. Clin Rheumatol 31(1):91–97 PubMedCrossRef Aytekin E et al (2012) Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions. Clin Rheumatol 31(1):91–97 PubMedCrossRef
351.
Zurück zum Zitat Colina M et al (2009) Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol 22(4):1125–1129 PubMedCrossRef Colina M et al (2009) Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol 22(4):1125–1129 PubMedCrossRef
352.
Zurück zum Zitat Karahan AY et al (2016) The effectiveness of Exergames in patients with Ankylosing Spondylitis: a randomized controlled trial. Adv Clin Exp Med 25(5):931–936 PubMedCrossRef Karahan AY et al (2016) The effectiveness of Exergames in patients with Ankylosing Spondylitis: a randomized controlled trial. Adv Clin Exp Med 25(5):931–936 PubMedCrossRef
353.
Zurück zum Zitat Kraag G et al (1990) The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—a randomized controlled trial. J Rheumatol 17(2):228–233 PubMed Kraag G et al (1990) The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—a randomized controlled trial. J Rheumatol 17(2):228–233 PubMed
354.
Zurück zum Zitat Ince G et al (2006) Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys Ther 86(7):924–935 PubMed Ince G et al (2006) Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys Ther 86(7):924–935 PubMed
355.
Zurück zum Zitat Lim HJ, Moon YI, Lee MS (2005) Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int 25(3):225–229 PubMedCrossRef Lim HJ, Moon YI, Lee MS (2005) Effects of home-based daily exercise therapy on joint mobility, daily activity, pain, and depression in patients with ankylosing spondylitis. Rheumatol Int 25(3):225–229 PubMedCrossRef
356.
Zurück zum Zitat Kraag G et al (1994) The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—an 8‑month followup. J Rheumatol 21(2):261–263 PubMed Kraag G et al (1994) The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis—an 8‑month followup. J Rheumatol 21(2):261–263 PubMed
357.
Zurück zum Zitat Karapolat H et al (2008) Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression. Clin Rheumatol 27(6):695–700 PubMedCrossRef Karapolat H et al (2008) Comparison of group-based exercise versus home-based exercise in patients with ankylosing spondylitis: effects on Bath Ankylosing Spondylitis Indices, quality of life and depression. Clin Rheumatol 27(6):695–700 PubMedCrossRef
358.
Zurück zum Zitat Hidding A et al (1993) Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 6(3):117–125 PubMedCrossRef Hidding A et al (1993) Is group physical therapy superior to individualized therapy in ankylosing spondylitis? A randomized controlled trial. Arthritis Care Res 6(3):117–125 PubMedCrossRef
359.
Zurück zum Zitat Helliwell P (1996) A randomised trial of three different physiotherapy regimes in ankylosing spondylitis. Physiotherapy 82:85–90 CrossRef Helliwell P (1996) A randomised trial of three different physiotherapy regimes in ankylosing spondylitis. Physiotherapy 82:85–90 CrossRef
360.
Zurück zum Zitat Analay Y et al (2003) The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clin Rehabil 17(6):631–636 PubMedCrossRef Analay Y et al (2003) The effectiveness of intensive group exercise on patients with ankylosing spondylitis. Clin Rehabil 17(6):631–636 PubMedCrossRef
361.
Zurück zum Zitat Bakker C et al (1994) Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. J Rheumatol 21(2):264–268 PubMed Bakker C et al (1994) Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. J Rheumatol 21(2):264–268 PubMed
362.
Zurück zum Zitat Ciprian L et al (2013) The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors. Rheumatol Int 33(1):241–245 PubMedCrossRef Ciprian L et al (2013) The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF inhibitors. Rheumatol Int 33(1):241–245 PubMedCrossRef
363.
Zurück zum Zitat Gurcay E et al (2008) Stanger bath therapy for ankylosing spondylitis: illusion or reality? Clin Rheumatol 27(7):913–917 PubMedCrossRef Gurcay E et al (2008) Stanger bath therapy for ankylosing spondylitis: illusion or reality? Clin Rheumatol 27(7):913–917 PubMedCrossRef
364.
Zurück zum Zitat Altan L et al (2006) The effect of balneotherapy on patients with ankylosing spondylitis. Scand J Rheumatol 35(4):283–289 PubMedCrossRef Altan L et al (2006) The effect of balneotherapy on patients with ankylosing spondylitis. Scand J Rheumatol 35(4):283–289 PubMedCrossRef
365.
Zurück zum Zitat Codish S et al (2005) Spa therapy for ankylosing spondylltis at the Dead Sea. Isr Med Assoc J 7(7):443–446 PubMed Codish S et al (2005) Spa therapy for ankylosing spondylltis at the Dead Sea. Isr Med Assoc J 7(7):443–446 PubMed
366.
Zurück zum Zitat Rutherford SM, Nicolson CF, Crowther ER (2005) Symptomatic improvement in function and disease activity in a patient with ankylosing spondylitis utilizing a course of chiropractic therapy: a prospective case study. J Can Chiropr Assoc 49(2):81–91 PubMedPubMedCentral Rutherford SM, Nicolson CF, Crowther ER (2005) Symptomatic improvement in function and disease activity in a patient with ankylosing spondylitis utilizing a course of chiropractic therapy: a prospective case study. J Can Chiropr Assoc 49(2):81–91 PubMedPubMedCentral
367.
Zurück zum Zitat Oosterveld FG et al (2009) Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. A pilot study showing good tolerance, short-term improvement of pain and stiffness, and a trend towards long-term beneficial effects. Clin Rheumatol 28(1):29–34 PubMedCrossRef Oosterveld FG et al (2009) Infrared sauna in patients with rheumatoid arthritis and ankylosing spondylitis. A pilot study showing good tolerance, short-term improvement of pain and stiffness, and a trend towards long-term beneficial effects. Clin Rheumatol 28(1):29–34 PubMedCrossRef
368.
Zurück zum Zitat Tarner IH et al (2009) The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 28(4):397–402 PubMedCrossRef Tarner IH et al (2009) The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol 28(4):397–402 PubMedCrossRef
369.
Zurück zum Zitat Samborski W et al (1992) Can thermal therapy of ankylosing spondylitis induce an activation of the disease? Z Rheumatol 51(3):127–131 PubMed Samborski W et al (1992) Can thermal therapy of ankylosing spondylitis induce an activation of the disease? Z Rheumatol 51(3):127–131 PubMed
370.
Zurück zum Zitat Gemignani G et al (1991) Transcutaneous electrical nerve stimulation in ankylosing spondylitis: a double-blind study. Arthritis Rheum 34(6):788–789 PubMedCrossRef Gemignani G et al (1991) Transcutaneous electrical nerve stimulation in ankylosing spondylitis: a double-blind study. Arthritis Rheum 34(6):788–789 PubMedCrossRef
371.
Zurück zum Zitat Turan Y et al (2014) Is magnetotherapy applied to bilateral hips effective in ankylosing spondylitis patients? A randomized, double-blind, controlled study. Rheumatol Int 34(3):357–365 PubMedCrossRef Turan Y et al (2014) Is magnetotherapy applied to bilateral hips effective in ankylosing spondylitis patients? A randomized, double-blind, controlled study. Rheumatol Int 34(3):357–365 PubMedCrossRef
372.
Zurück zum Zitat Silte Karamanlioglu D et al (2016) Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double-blind, randomized, placebo-controlled trial. Rheumatol Int 36(5):653–661 PubMedCrossRef Silte Karamanlioglu D et al (2016) Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double-blind, randomized, placebo-controlled trial. Rheumatol Int 36(5):653–661 PubMedCrossRef
373.
Zurück zum Zitat Spadaro A et al (2008) Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. Joint Bone Spine 75(1):29–33 PubMedCrossRef Spadaro A et al (2008) Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. Joint Bone Spine 75(1):29–33 PubMedCrossRef
374.
Zurück zum Zitat Barkhuizen A et al (2006) Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 33(9):1805–1812 PubMed Barkhuizen A et al (2006) Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 33(9):1805–1812 PubMed
375.
Zurück zum Zitat Dougados M et al (1989) A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol 16(8):1167–1169 PubMed Dougados M et al (1989) A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol 16(8):1167–1169 PubMed
376.
Zurück zum Zitat Dougados M et al (1994) Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 23(5):243–248 PubMedCrossRef Dougados M et al (1994) Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 23(5):243–248 PubMedCrossRef
377.
Zurück zum Zitat Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 33(2):129–131 PubMedPubMedCentralCrossRef Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 33(2):129–131 PubMedPubMedCentralCrossRef
378.
Zurück zum Zitat van der Heijde D et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52(4):1205–1215 PubMedCrossRef van der Heijde D et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52(4):1205–1215 PubMedCrossRef
379.
Zurück zum Zitat Kroon FP et al (2016) Nonsteroidal antiinflammatory drugs for axial Spondyloarthritis: a Cochrane review. J Rheumatol 43(3):607–617 PubMedCrossRef Kroon FP et al (2016) Nonsteroidal antiinflammatory drugs for axial Spondyloarthritis: a Cochrane review. J Rheumatol 43(3):607–617 PubMedCrossRef
380.
Zurück zum Zitat Wang R, Dasgupta A, Ward MM (2016) Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis 75(6):1152–1160 PubMedCrossRef Wang R, Dasgupta A, Ward MM (2016) Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis 75(6):1152–1160 PubMedCrossRef
381.
Zurück zum Zitat Sieper J et al (2014) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73(1):101–107 PubMedCrossRef Sieper J et al (2014) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73(1):101–107 PubMedCrossRef
382.
Zurück zum Zitat Gossec L et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64(11):1563–1567 PubMedPubMedCentralCrossRef Gossec L et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64(11):1563–1567 PubMedPubMedCentralCrossRef
383.
Zurück zum Zitat Sieper J et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67(3):323–329 PubMedCrossRef Sieper J et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67(3):323–329 PubMedCrossRef
384.
Zurück zum Zitat Escalas C, Trijau S, Dougados M (2010) Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatol (oxford) 49(7):1317–1325 CrossRef Escalas C, Trijau S, Dougados M (2010) Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatol (oxford) 49(7):1317–1325 CrossRef
385.
Zurück zum Zitat Walker C et al (2016) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J Int Med Res 44(3):483–495 PubMedPubMedCentralCrossRef Walker C et al (2016) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J Int Med Res 44(3):483–495 PubMedPubMedCentralCrossRef
386.
Zurück zum Zitat Balazcs E et al (2016) A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. Bmc Musculoskelet Disord 17(1):426 PubMedPubMedCentralCrossRef Balazcs E et al (2016) A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. Bmc Musculoskelet Disord 17(1):426 PubMedPubMedCentralCrossRef
387.
Zurück zum Zitat Peloso PM et al (2011) Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. Bmc Musculoskelet Disord 12:165 PubMedPubMedCentralCrossRef Peloso PM et al (2011) Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. Bmc Musculoskelet Disord 12:165 PubMedPubMedCentralCrossRef
388.
Zurück zum Zitat Dougados M et al (2014) Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther 16(6):481 PubMedPubMedCentralCrossRef Dougados M et al (2014) Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther 16(6):481 PubMedPubMedCentralCrossRef
389.
Zurück zum Zitat van der Heijde D et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6):905–908 PubMedCrossRef van der Heijde D et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6):905–908 PubMedCrossRef
390.
Zurück zum Zitat Zochling J et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol 25(6):794–800 PubMedCrossRef Zochling J et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol 25(6):794–800 PubMedCrossRef
391.
Zurück zum Zitat Wanders A et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756–1765 PubMedCrossRef Wanders A et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756–1765 PubMedCrossRef
392.
Zurück zum Zitat Sieper J et al (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75(8):1438–1443 PubMedCrossRef Sieper J et al (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75(8):1438–1443 PubMedCrossRef
393.
Zurück zum Zitat Colebatch AN, Marks JL, Edwards CJ (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011(11):CD8872 Colebatch AN, Marks JL, Edwards CJ (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011(11):CD8872
394.
Zurück zum Zitat Kristensen LE et al (2015) Safety of Etoricoxib, Celecoxib, and nonselective Nonsteroidal antiinflammatory drugs in Ankylosing Spondylitis and other Spondyloarthritis patients: a Swedish national population-based cohort study. Arthritis Care Res (hoboken) 67(8):1137–1149 CrossRef Kristensen LE et al (2015) Safety of Etoricoxib, Celecoxib, and nonselective Nonsteroidal antiinflammatory drugs in Ankylosing Spondylitis and other Spondyloarthritis patients: a Swedish national population-based cohort study. Arthritis Care Res (hoboken) 67(8):1137–1149 CrossRef
395.
Zurück zum Zitat Cannon CP et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368(9549):1771–1781 PubMedCrossRef Cannon CP et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368(9549):1771–1781 PubMedCrossRef
396.
Zurück zum Zitat Farkouh ME et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364(9435):675–684 PubMedCrossRef Farkouh ME et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364(9435):675–684 PubMedCrossRef
397.
Zurück zum Zitat Song IH et al (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58(4):929–938 PubMedCrossRef Song IH et al (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58(4):929–938 PubMedCrossRef
398.
Zurück zum Zitat Bally M et al (2017) Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 357:j1909 PubMedPubMedCentralCrossRef Bally M et al (2017) Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 357:j1909 PubMedPubMedCentralCrossRef
399.
Zurück zum Zitat Fanelli A et al (2017) Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 8(6):173–182 PubMedPubMedCentralCrossRef Fanelli A et al (2017) Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 8(6):173–182 PubMedPubMedCentralCrossRef
401.
Zurück zum Zitat Burmester G et al (2011) The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 70(5):818–822 PubMedCrossRef Burmester G et al (2011) The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 70(5):818–822 PubMedCrossRef
402.
Zurück zum Zitat Arzneimittelkommission der deutschen Ärzteschaft (2008) Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen. 35(Sonderheft 1) Arzneimittelkommission der deutschen Ärzteschaft (2008) Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen. 35(Sonderheft 1)
403.
Zurück zum Zitat Lanza FL et al (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104(3):728–738 PubMed Lanza FL et al (2009) Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104(3):728–738 PubMed
404.
Zurück zum Zitat Yokoyama H et al (2013) Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther 38(1):12–15 PubMedCrossRef Yokoyama H et al (2013) Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin. J Clin Pharm Ther 38(1):12–15 PubMedCrossRef
405.
Zurück zum Zitat Catella-Lawson F et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817 PubMedCrossRef Catella-Lawson F et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345(25):1809–1817 PubMedCrossRef
406.
Zurück zum Zitat Zhang X et al (2017) Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. Bmc Nephrol 18(1):256 PubMedPubMedCentralCrossRef Zhang X et al (2017) Non-steroidal anti-inflammatory drug induced acute kidney injury in the community dwelling general population and people with chronic kidney disease: systematic review and meta-analysis. Bmc Nephrol 18(1):256 PubMedPubMedCentralCrossRef
407.
Zurück zum Zitat Gooch K et al (2007) NSAID use and progression of chronic kidney disease. Am J Med 120(3):280 e1–280 e7 CrossRef Gooch K et al (2007) NSAID use and progression of chronic kidney disease. Am J Med 120(3):280 e1–280 e7 CrossRef
408.
Zurück zum Zitat Basavaraj KH et al (2010) The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 49(12):1351–1361 PubMedCrossRef Basavaraj KH et al (2010) The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 49(12):1351–1361 PubMedCrossRef
409.
Zurück zum Zitat Gossec L et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510 PubMedCrossRef Gossec L et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499–510 PubMedCrossRef
410.
Zurück zum Zitat Canoui-Poitrine F et al (2014) Early tumor necrosis factor alpha antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort. Arthritis Care Res (hoboken) 66(9):1395–1402 CrossRef Canoui-Poitrine F et al (2014) Early tumor necrosis factor alpha antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort. Arthritis Care Res (hoboken) 66(9):1395–1402 CrossRef
411.
Zurück zum Zitat Chen C et al (2016) Comparative effectiveness of biologic therapy regimens for Ankylosing Spondylitis: a systematic review and a network Meta-analysis. Medicine (Baltimore) 95(11):e3060 CrossRef Chen C et al (2016) Comparative effectiveness of biologic therapy regimens for Ankylosing Spondylitis: a systematic review and a network Meta-analysis. Medicine (Baltimore) 95(11):e3060 CrossRef
412.
Zurück zum Zitat Betts KA et al (2016) Network Meta-analysis and cost Per responder of tumor necrosis factor-alpha and Interleukin inhibitors in the treatment of active Ankylosing Spondylitis. Rheumatol Ther 3(2):323–336 PubMedPubMedCentralCrossRef Betts KA et al (2016) Network Meta-analysis and cost Per responder of tumor necrosis factor-alpha and Interleukin inhibitors in the treatment of active Ankylosing Spondylitis. Rheumatol Ther 3(2):323–336 PubMedPubMedCentralCrossRef
413.
Zurück zum Zitat Callhoff J et al (2015) Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74(6):1241–1248 PubMedCrossRef Callhoff J et al (2015) Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74(6):1241–1248 PubMedCrossRef
414.
Zurück zum Zitat Li ZH et al (2013) Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol 23(5):497–506 PubMedCrossRef Li ZH et al (2013) Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol 23(5):497–506 PubMedCrossRef
415.
Zurück zum Zitat Wang H et al (2014) Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis. Int J Rheum Dis 17(2):142–148 PubMedCrossRef Wang H et al (2014) Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis. Int J Rheum Dis 17(2):142–148 PubMedCrossRef
416.
Zurück zum Zitat Wang Y et al (2016) Comparative efficacy and acceptability of anti-TNF-Alpha therapy in Ankylosing Spondylitis: a mixed-treatments comparison. Cell Physiol Biochem 39(5):1679–1694 PubMedCrossRef Wang Y et al (2016) Comparative efficacy and acceptability of anti-TNF-Alpha therapy in Ankylosing Spondylitis: a mixed-treatments comparison. Cell Physiol Biochem 39(5):1679–1694 PubMedCrossRef
417.
Zurück zum Zitat Braun J et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505 PubMedCrossRef Braun J et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505 PubMedCrossRef
418.
Zurück zum Zitat Zochling J et al (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65(4):423–432 PubMedCrossRef Zochling J et al (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65(4):423–432 PubMedCrossRef
419.
Zurück zum Zitat Sepriano A et al (2017) Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e396 PubMedPubMedCentralCrossRef Sepriano A et al (2017) Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e396 PubMedPubMedCentralCrossRef
420.
Zurück zum Zitat Maxwell LJ et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015(4):CD5468 Maxwell LJ et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 2015(4):CD5468
421.
Zurück zum Zitat Olivieri I et al (2016) Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis. Clin Exp Rheumatol 34(5):935–940 PubMed Olivieri I et al (2016) Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis. Clin Exp Rheumatol 34(5):935–940 PubMed
422.
Zurück zum Zitat Ren L et al (2013) Efficacy of antitumor necrosis factor(alpha) agents on patients with ankylosing spondylitis. Am J Med Sci 346(6):455–461 PubMedCrossRef Ren L et al (2013) Efficacy of antitumor necrosis factor(alpha) agents on patients with ankylosing spondylitis. Am J Med Sci 346(6):455–461 PubMedCrossRef
423.
Zurück zum Zitat van der Heijde D et al (2008) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67(9):1218–1221 PubMedCrossRef van der Heijde D et al (2008) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67(9):1218–1221 PubMedCrossRef
424.
Zurück zum Zitat Dougados M et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799–804 PubMedCrossRef Dougados M et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799–804 PubMedCrossRef
425.
Zurück zum Zitat Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58(7):1981–1991 PubMedCrossRef Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58(7):1981–1991 PubMedCrossRef
426.
Zurück zum Zitat Song IH et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70(4):590–596 PubMedCrossRef Song IH et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70(4):590–596 PubMedCrossRef
427.
Zurück zum Zitat Barkham N et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946–954 PubMedCrossRef Barkham N et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946–954 PubMedCrossRef
428.
Zurück zum Zitat Sieper J et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72(6):815–822 PubMedCrossRef Sieper J et al (2013) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 72(6):815–822 PubMedCrossRef
429.
Zurück zum Zitat Corbett M et al (2016) Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess 20(9):1–334 PubMedPubMedCentralCrossRef Corbett M et al (2016) Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess 20(9):1–334 PubMedPubMedCentralCrossRef
430.
Zurück zum Zitat Ciurea A et al (2013) Tumor necrosis factor alpha inhibition in radiographic and Nonradiographic axial Spondyloarthritis: results from a large observational cohort. Arthritis Rheum 65(12):3096–3106 PubMedCrossRef Ciurea A et al (2013) Tumor necrosis factor alpha inhibition in radiographic and Nonradiographic axial Spondyloarthritis: results from a large observational cohort. Arthritis Rheum 65(12):3096–3106 PubMedCrossRef
431.
Zurück zum Zitat Corli J et al (2015) Tumor necrosis factor-alpha inhibition in Ankylosing Spondylitis and Nonradiographic axial Spondyloarthritis: treatment response, drug survival, and patient outcome. J Rheumatol 42(12):2376–2382 PubMedCrossRef Corli J et al (2015) Tumor necrosis factor-alpha inhibition in Ankylosing Spondylitis and Nonradiographic axial Spondyloarthritis: treatment response, drug survival, and patient outcome. J Rheumatol 42(12):2376–2382 PubMedCrossRef
432.
Zurück zum Zitat Kristensen LE et al (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (hoboken) 62(10):1362–1369 CrossRef Kristensen LE et al (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (hoboken) 62(10):1362–1369 CrossRef
433.
Zurück zum Zitat Arends S et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94 PubMedPubMedCentralCrossRef Arends S et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94 PubMedPubMedCentralCrossRef
434.
Zurück zum Zitat Vastesaeger N et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70(6):973–981 PubMedCrossRef Vastesaeger N et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70(6):973–981 PubMedCrossRef
435.
Zurück zum Zitat Maneiro JR et al (2015) Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 1(1):e17 PubMedPubMedCentralCrossRef Maneiro JR et al (2015) Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 1(1):e17 PubMedPubMedCentralCrossRef
436.
Zurück zum Zitat van der Heijde D et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146 PubMedCrossRef van der Heijde D et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146 PubMedCrossRef
437.
Zurück zum Zitat van der Heijde D et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922–929 PubMedCrossRef van der Heijde D et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922–929 PubMedCrossRef
438.
Zurück zum Zitat Davis JC Jr. et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236 PubMedCrossRef Davis JC Jr. et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236 PubMedCrossRef
439.
Zurück zum Zitat Davis JC et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64(11):1557–1562 PubMedPubMedCentralCrossRef Davis JC et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64(11):1557–1562 PubMedPubMedCentralCrossRef
440.
Zurück zum Zitat Davis JC Jr. et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346–352 PubMedCrossRef Davis JC Jr. et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346–352 PubMedCrossRef
441.
Zurück zum Zitat Calin A et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600 PubMedPubMedCentralCrossRef Calin A et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600 PubMedPubMedCentralCrossRef
442.
Zurück zum Zitat Dijkmans B et al (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36(6):1256–1264 PubMedCrossRef Dijkmans B et al (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36(6):1256–1264 PubMedCrossRef
443.
Zurück zum Zitat Martin-Mola E et al (2010) Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(2):238–245 PubMed Martin-Mola E et al (2010) Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(2):238–245 PubMed
444.
Zurück zum Zitat van der Heijde D et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572–1577 PubMedPubMedCentralCrossRef van der Heijde D et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572–1577 PubMedPubMedCentralCrossRef
445.
Zurück zum Zitat Dougados M et al (2010) A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 69(8):1430–1435 PubMedCrossRef Dougados M et al (2010) A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 69(8):1430–1435 PubMedCrossRef
446.
Zurück zum Zitat Navarro-Sarabia F et al (2011) High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatol (oxford) 50(10):1828–1837 CrossRef Navarro-Sarabia F et al (2011) High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatol (oxford) 50(10):1828–1837 CrossRef
447.
Zurück zum Zitat Braun J et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543–1551 PubMedCrossRef Braun J et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543–1551 PubMedCrossRef
448.
Zurück zum Zitat Inman RD et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412 PubMedCrossRef Inman RD et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412 PubMedCrossRef
449.
Zurück zum Zitat Braun J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193 PubMedCrossRef Braun J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193 PubMedCrossRef
450.
Zurück zum Zitat Braun J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2):229–234 PubMedCrossRef Braun J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2):229–234 PubMedCrossRef
451.
Zurück zum Zitat Braun J et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatol (oxford) 44(5):670–676 CrossRef Braun J et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatol (oxford) 44(5):670–676 CrossRef
452.
Zurück zum Zitat Braun J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345 PubMedCrossRef Braun J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345 PubMedCrossRef
453.
Zurück zum Zitat Baraliakos X et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatol (oxford) 50(9):1690–1699 CrossRef Baraliakos X et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years—early clinical response predicts long-term outcome. Rheumatol (oxford) 50(9):1690–1699 CrossRef
454.
Zurück zum Zitat van der Heijde D et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591 PubMedCrossRef van der Heijde D et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591 PubMedCrossRef
455.
Zurück zum Zitat Heldmann F et al (2011) The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 29(4):672–680 PubMed Heldmann F et al (2011) The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 29(4):672–680 PubMed
456.
Zurück zum Zitat Bao C et al (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1‑year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatol (oxford) 53(9):1654–1663 CrossRef Bao C et al (2014) Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1‑year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. Rheumatol (oxford) 53(9):1654–1663 CrossRef
457.
Zurück zum Zitat Deodhar A et al (2018) Safety and efficacy of Golimumab administered intravenously in adults with Ankylosing Spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol 45(3):341–348 PubMedCrossRef Deodhar A et al (2018) Safety and efficacy of Golimumab administered intravenously in adults with Ankylosing Spondylitis: results through week 28 of the GO-ALIVE study. J Rheumatol 45(3):341–348 PubMedCrossRef
458.
Zurück zum Zitat Dougados M et al (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66(8):2091–2102 PubMedCrossRef Dougados M et al (2014) Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 66(8):2091–2102 PubMedCrossRef
459.
Zurück zum Zitat Huang F et al (2014) Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73(3):587–594 PubMedCrossRef Huang F et al (2014) Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial. Ann Rheum Dis 73(3):587–594 PubMedCrossRef
460.
Zurück zum Zitat Landewe R et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73(1):39–47 PubMedCrossRef Landewe R et al (2014) Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 73(1):39–47 PubMedCrossRef
461.
Zurück zum Zitat Park W et al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72(10):1605–1612 PubMedCrossRef Park W et al (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72(10):1605–1612 PubMedCrossRef
462.
Zurück zum Zitat Cohen JD et al (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 34(2):380–385 PubMed Cohen JD et al (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 34(2):380–385 PubMed
463.
Zurück zum Zitat Davis JC Jr. et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050–1057 PubMedCrossRef Davis JC Jr. et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050–1057 PubMedCrossRef
464.
Zurück zum Zitat Braun J et al (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatol (oxford) 46(6):999–1004 CrossRef Braun J et al (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatol (oxford) 46(6):999–1004 CrossRef
465.
Zurück zum Zitat Boonen A et al (2008) Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662–667 PubMed Boonen A et al (2008) Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662–667 PubMed
466.
Zurück zum Zitat Kimel M et al (2011) Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clin Exp Rheumatol 29(4):624–632 PubMed Kimel M et al (2011) Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clin Exp Rheumatol 29(4):624–632 PubMed
467.
Zurück zum Zitat Braun J et al (2009) Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 61(8):1032–1036 PubMedCrossRef Braun J et al (2009) Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 61(8):1032–1036 PubMedCrossRef
468.
Zurück zum Zitat Gonnet-Gracia C et al (2008) Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 26(3):401–407 PubMed Gonnet-Gracia C et al (2008) Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 26(3):401–407 PubMed
469.
Zurück zum Zitat Maksymowych WP et al (2010) Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37(8):1728–1734 PubMedCrossRef Maksymowych WP et al (2010) Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37(8):1728–1734 PubMedCrossRef
470.
Zurück zum Zitat van der Heijde D et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331 PubMedCrossRef van der Heijde D et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331 PubMedCrossRef
471.
Zurück zum Zitat Baraliakos X et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatol (oxford) 46(9):1450–1453 CrossRef Baraliakos X et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatol (oxford) 46(9):1450–1453 CrossRef
472.
Zurück zum Zitat Haroon N et al (2013) The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65(10):2645–2654 PubMedPubMedCentral Haroon N et al (2013) The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65(10):2645–2654 PubMedPubMedCentral
473.
Zurück zum Zitat Kim TJ et al (2016) Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data. Joint Bone Spine 83(5):569–572 PubMedCrossRef Kim TJ et al (2016) Radiographic progression in patients with ankylosing spondylitis according to tumor necrosis factor blocker exposure: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) data. Joint Bone Spine 83(5):569–572 PubMedCrossRef
474.
Zurück zum Zitat Maas F et al (2017) Reduction in spinal radiographic progression in Ankylosing Spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res (hoboken) 69(7):1011–1019 CrossRef Maas F et al (2017) Reduction in spinal radiographic progression in Ankylosing Spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res (hoboken) 69(7):1011–1019 CrossRef
475.
Zurück zum Zitat Molnar C et al (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77(1):63–69 PubMedCrossRef Molnar C et al (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77(1):63–69 PubMedCrossRef
476.
Zurück zum Zitat Park JW et al (2016) Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in Ankylosing Spondylitis. PLoS ONE 11(12):e168958 PubMedPubMedCentralCrossRef Park JW et al (2016) Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in Ankylosing Spondylitis. PLoS ONE 11(12):e168958 PubMedPubMedCentralCrossRef
477.
Zurück zum Zitat Visvanathan S et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68(2):175–182 PubMedCrossRef Visvanathan S et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68(2):175–182 PubMedCrossRef
478.
Zurück zum Zitat Siu S et al (2015) Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (hoboken) 67(6):754–764 CrossRef Siu S et al (2015) Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (hoboken) 67(6):754–764 CrossRef
479.
Zurück zum Zitat van der Heijde D et al (2006) Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 55(4):569–574 PubMedCrossRef van der Heijde D et al (2006) Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 55(4):569–574 PubMedCrossRef
480.
Zurück zum Zitat Barkham N et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928 PubMedCrossRef Barkham N et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928 PubMedCrossRef
481.
Zurück zum Zitat Keat AC et al (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatol (oxford) 47(4):481–483 CrossRef Keat AC et al (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatol (oxford) 47(4):481–483 CrossRef
482.
Zurück zum Zitat Kristensen LE et al (2012) Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford) 51(2):243–249 CrossRef Kristensen LE et al (2012) Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford) 51(2):243–249 CrossRef
483.
Zurück zum Zitat Maksymowych WP et al (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37(2):385–392 PubMedCrossRef Maksymowych WP et al (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37(2):385–392 PubMedCrossRef
484.
Zurück zum Zitat Wallman JK et al (2017) Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. Rheumatology (Oxford) 56(5):716–724 Wallman JK et al (2017) Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden. Rheumatology (Oxford) 56(5):716–724
485.
Zurück zum Zitat Baeten D et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705–1713 PubMedCrossRef Baeten D et al (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705–1713 PubMedCrossRef
486.
Zurück zum Zitat Baeten D et al (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373(26):2534–2548 PubMedCrossRef Baeten D et al (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 373(26):2534–2548 PubMedCrossRef
487.
Zurück zum Zitat Sieper J et al (2017) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 76(3):571–592 PubMedCrossRef Sieper J et al (2017) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 76(3):571–592 PubMedCrossRef
488.
Zurück zum Zitat Pavelka K et al (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 19(1):285 PubMedPubMedCentralCrossRef Pavelka K et al (2017) Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther 19(1):285 PubMedPubMedCentralCrossRef
489.
Zurück zum Zitat Deodhar AA et al (2016) Effect of Secukinumab on patient-reported outcomes in patients with active Ankylosing Spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 68(12):2901–2910 PubMedPubMedCentralCrossRef Deodhar AA et al (2016) Effect of Secukinumab on patient-reported outcomes in patients with active Ankylosing Spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 68(12):2901–2910 PubMedPubMedCentralCrossRef
490.
Zurück zum Zitat Deodhar A et al (2019) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C‑reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2‑year data from the MEASURE 2 study. Clin Exp Rheumatol 37(2):260–269 PubMed Deodhar A et al (2019) Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C‑reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2‑year data from the MEASURE 2 study. Clin Exp Rheumatol 37(2):260–269 PubMed
491.
Zurück zum Zitat Baraliakos X et al (2016) Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis 75(2):408–412 PubMedCrossRef Baraliakos X et al (2016) Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis 75(2):408–412 PubMedCrossRef
492.
Zurück zum Zitat Baraliakos X et al (2018) Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3‑year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 36(1):50–55 PubMed Baraliakos X et al (2018) Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3‑year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol 36(1):50–55 PubMed
493.
Zurück zum Zitat Braun J et al (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2‑year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070–1077 PubMedCrossRef Braun J et al (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2‑year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070–1077 PubMedCrossRef
494.
Zurück zum Zitat Marzo-Ortega H et al (2017) Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3‑year results from the phase III trial, MEASURE 2. RMD Open 3(2):e592 PubMedPubMedCentralCrossRef Marzo-Ortega H et al (2017) Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3‑year results from the phase III trial, MEASURE 2. RMD Open 3(2):e592 PubMedPubMedCentralCrossRef
495.
Zurück zum Zitat Song IH et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290–1297 PubMedCrossRef Song IH et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290–1297 PubMedCrossRef
496.
Zurück zum Zitat Song IH et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70(6):1108–1110 PubMedCrossRef Song IH et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70(6):1108–1110 PubMedCrossRef
497.
Zurück zum Zitat Sieper J et al (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74(6):1051–1057 PubMedCrossRef Sieper J et al (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74(6):1051–1057 PubMedCrossRef
498.
Zurück zum Zitat Sieper J et al (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73(19):95–100 PubMedCrossRef Sieper J et al (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73(19):95–100 PubMedCrossRef
499.
Zurück zum Zitat Poddubnyy D et al (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73(5):817–823 PubMedCrossRef Poddubnyy D et al (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73(5):817–823 PubMedCrossRef
500.
Zurück zum Zitat Deodhar A et al (2019) Three Multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial Spondyloarthritis. Arthritis Rheumatol 71(2):258–270 PubMedCrossRef Deodhar A et al (2019) Three Multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of Ustekinumab in axial Spondyloarthritis. Arthritis Rheumatol 71(2):258–270 PubMedCrossRef
501.
Zurück zum Zitat Heiberg MS et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59(2):234–240 PubMedCrossRef Heiberg MS et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59(2):234–240 PubMedCrossRef
502.
Zurück zum Zitat Glintborg B et al (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72(7):1149–1155 PubMedCrossRef Glintborg B et al (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72(7):1149–1155 PubMedCrossRef
503.
Zurück zum Zitat Ciurea A et al (2016) Impaired response to treatment with tumour necrosis factor alpha inhibitors in smokers with axial spondyloarthritis. Ann Rheum Dis 75(3):532–539 PubMedCrossRef Ciurea A et al (2016) Impaired response to treatment with tumour necrosis factor alpha inhibitors in smokers with axial spondyloarthritis. Ann Rheum Dis 75(3):532–539 PubMedCrossRef
504.
Zurück zum Zitat Glintborg B et al (2016) Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatol (oxford) 55(4):659–668 CrossRef Glintborg B et al (2016) Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatol (oxford) 55(4):659–668 CrossRef
505.
Zurück zum Zitat Micheroli R et al (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19(1):164 PubMedPubMedCentralCrossRef Micheroli R et al (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19(1):164 PubMedPubMedCentralCrossRef
506.
Zurück zum Zitat Breban M et al (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58(1):88–97 PubMedCrossRef Breban M et al (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58(1):88–97 PubMedCrossRef
507.
Zurück zum Zitat Marzo-Ortega H et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575 PubMedPubMedCentralCrossRef Marzo-Ortega H et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575 PubMedPubMedCentralCrossRef
508.
Zurück zum Zitat Li EK et al (2008) Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatol (oxford) 47(9):1358–1363 CrossRef Li EK et al (2008) Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatol (oxford) 47(9):1358–1363 CrossRef
509.
Zurück zum Zitat Perez-Guijo VC et al (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258 PubMedCrossRef Perez-Guijo VC et al (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258 PubMedCrossRef
510.
Zurück zum Zitat Ma Z et al (2017) Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: a meta-analysis. Medicine (Baltimore) 96(25):e7145 CrossRef Ma Z et al (2017) Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: a meta-analysis. Medicine (Baltimore) 96(25):e7145 CrossRef
511.
Zurück zum Zitat Diel R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63(6):329–334 PubMedCrossRef Diel R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63(6):329–334 PubMedCrossRef
512.
Zurück zum Zitat Fouque-Aubert A et al (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69(10):1756–1761 PubMedCrossRef Fouque-Aubert A et al (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69(10):1756–1761 PubMedCrossRef
513.
Zurück zum Zitat Xu Z et al (2017) Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta-analysis of randomized controlled trials. Exp Ther Med 14(4):3491–3500 PubMedPubMedCentralCrossRef Xu Z et al (2017) Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta-analysis of randomized controlled trials. Exp Ther Med 14(4):3491–3500 PubMedPubMedCentralCrossRef
514.
Zurück zum Zitat Mariette X et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–1904 PubMedCrossRef Mariette X et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–1904 PubMedCrossRef
515.
Zurück zum Zitat Baraliakos X et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444 PubMedPubMedCentralCrossRef Baraliakos X et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444 PubMedPubMedCentralCrossRef
516.
Zurück zum Zitat Landewe R et al (2018) Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 392(10142):134–144 PubMedCrossRef Landewe R et al (2018) Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 392(10142):134–144 PubMedCrossRef
517.
Zurück zum Zitat Sieper J et al (2014) Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73(1):108–113 PubMedCrossRef Sieper J et al (2014) Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73(1):108–113 PubMedCrossRef
518.
Zurück zum Zitat Fong W et al (2016) The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. Rheumatol (oxford) 55(10):1837–1842 CrossRef Fong W et al (2016) The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. Rheumatol (oxford) 55(10):1837–1842 CrossRef
519.
Zurück zum Zitat Inman RD, Maksymowych WP (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37(6):1203–1210 PubMedCrossRef Inman RD, Maksymowych WP (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37(6):1203–1210 PubMedCrossRef
520.
Zurück zum Zitat Krzysiek R et al (2009) Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 61(5):569–576 PubMedCrossRef Krzysiek R et al (2009) Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 61(5):569–576 PubMedCrossRef
521.
Zurück zum Zitat Arends S et al (2010) The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668 PubMed Arends S et al (2010) The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668 PubMed
522.
Zurück zum Zitat de Vries MK et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252–1254 PubMedPubMedCentralCrossRef de Vries MK et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252–1254 PubMedPubMedCentralCrossRef
523.
Zurück zum Zitat de Vries MK et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68(4):531–535 PubMedCrossRef de Vries MK et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68(4):531–535 PubMedCrossRef
524.
Zurück zum Zitat Lie E et al (2011) Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70(1):157–163 PubMedCrossRef Lie E et al (2011) Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70(1):157–163 PubMedCrossRef
525.
Zurück zum Zitat Ciurea A et al (2016) Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther 18:71 PubMedPubMedCentralCrossRef Ciurea A et al (2016) Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort. Arthritis Res Ther 18:71 PubMedPubMedCentralCrossRef
526.
Zurück zum Zitat Navarro-Compan V et al (2017) Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open 3(2):e524 PubMedPubMedCentralCrossRef Navarro-Compan V et al (2017) Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review. RMD Open 3(2):e524 PubMedPubMedCentralCrossRef
527.
Zurück zum Zitat Deodhar A, Yu D (2017) Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 47(3):343–350 PubMedCrossRef Deodhar A, Yu D (2017) Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum 47(3):343–350 PubMedCrossRef
528.
Zurück zum Zitat Sepriano A et al (2016) Effect of Comedication with conventional synthetic disease-modifying Antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with Spondyloarthritis: a prospective cohort study. Arthritis Rheumatol 68(11):2671–2679 PubMedCrossRef Sepriano A et al (2016) Effect of Comedication with conventional synthetic disease-modifying Antirheumatic drugs on retention of tumor necrosis factor inhibitors in patients with Spondyloarthritis: a prospective cohort study. Arthritis Rheumatol 68(11):2671–2679 PubMedCrossRef
529.
Zurück zum Zitat Nissen MJ et al (2016) The effect of Comedication with a conventional synthetic disease-modifying Antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial Spondyloarthritis. Arthritis Rheumatol 68(9):2141–2150 PubMedCrossRef Nissen MJ et al (2016) The effect of Comedication with a conventional synthetic disease-modifying Antirheumatic drug on drug retention and clinical effectiveness of anti-tumor necrosis factor therapy in patients with axial Spondyloarthritis. Arthritis Rheumatol 68(9):2141–2150 PubMedCrossRef
530.
Zurück zum Zitat Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005(2):CD4800 Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005(2):CD4800
531.
Zurück zum Zitat Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014(11):CD4800 Chen J, Lin S, Liu C (2014) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2014(11):CD4800
532.
Zurück zum Zitat Fagerli KM et al (2014) Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study. Rheumatol (oxford) 53(6):1087–1094 CrossRef Fagerli KM et al (2014) Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study. Rheumatol (oxford) 53(6):1087–1094 CrossRef
533.
Zurück zum Zitat Genc H et al (2007) The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. Clin Rheumatol 26(7):1104–1110 PubMedCrossRef Genc H et al (2007) The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. Clin Rheumatol 26(7):1104–1110 PubMedCrossRef
534.
Zurück zum Zitat Braun J et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153 PubMedPubMedCentralCrossRef Braun J et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153 PubMedPubMedCentralCrossRef
535.
Zurück zum Zitat Khanna Sharma S et al (2018) A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis 21(1):308–314 PubMedCrossRef Khanna Sharma S et al (2018) A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis 21(1):308–314 PubMedCrossRef
536.
Zurück zum Zitat Liu YF et al (2014) Etanercept in the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Exp Ther Med 8(5):1585–1592 PubMedPubMedCentralCrossRef Liu YF et al (2014) Etanercept in the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Exp Ther Med 8(5):1585–1592 PubMedPubMedCentralCrossRef
537.
Zurück zum Zitat Deng X et al (2013) Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int 33(6):1409–1413 PubMedCrossRef Deng X et al (2013) Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int 33(6):1409–1413 PubMedCrossRef
538.
Zurück zum Zitat Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006(4):CD4524 Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2006(4):CD4524
539.
Zurück zum Zitat Chen J et al (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev CD004524:2 Chen J et al (2013) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev CD004524:2
540.
Zurück zum Zitat Haibel H et al (2014) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 73(1):243–246 PubMedCrossRef Haibel H et al (2014) Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 73(1):243–246 PubMedCrossRef
541.
Zurück zum Zitat Maksymowych WP et al (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46(3):766–773 PubMedCrossRef Maksymowych WP et al (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46(3):766–773 PubMedCrossRef
542.
Zurück zum Zitat Haibel H et al (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatol (oxford) 42(8):1018–1020 CrossRef Haibel H et al (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatol (oxford) 42(8):1018–1020 CrossRef
543.
Zurück zum Zitat Cairns AP et al (2005) An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 64(2):338–339 PubMedCrossRef Cairns AP et al (2005) An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 64(2):338–339 PubMedCrossRef
544.
Zurück zum Zitat Malaviya AN et al (2007) A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55:193–197 PubMed Malaviya AN et al (2007) A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55:193–197 PubMed
545.
Zurück zum Zitat Santra G et al (2010) Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J 51(11):883–887 PubMed Santra G et al (2010) Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J 51(11):883–887 PubMed
546.
Zurück zum Zitat Coates L et al (2017) Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. Clin Exp Rheumatol 35(3):445–451 PubMed Coates L et al (2017) Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. Clin Exp Rheumatol 35(3):445–451 PubMed
547.
Zurück zum Zitat Chatfield SM et al (2009) Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 28(2):213–217 PubMedCrossRef Chatfield SM et al (2009) Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 28(2):213–217 PubMedCrossRef
548.
Zurück zum Zitat Brophy S et al (2008) Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. Bmc Musculoskelet Disord 9:4 PubMedPubMedCentralCrossRef Brophy S et al (2008) Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. Bmc Musculoskelet Disord 9:4 PubMedPubMedCentralCrossRef
549.
Zurück zum Zitat Jenks K et al (2010) Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 37(10):2118–2125 PubMedCrossRef Jenks K et al (2010) Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 37(10):2118–2125 PubMedCrossRef
550.
Zurück zum Zitat Gotestam Skorpen C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810 PubMedCrossRef Gotestam Skorpen C et al (2016) The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75(5):795–810 PubMedCrossRef
551.
Zurück zum Zitat Flint J et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatol (oxford) 55(9):1693–1697 CrossRef Flint J et al (2016) BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatol (oxford) 55(9):1693–1697 CrossRef
552.
Zurück zum Zitat Villiger PM et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69(10):1842–1844 PubMedCrossRef Villiger PM et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69(10):1842–1844 PubMedCrossRef
553.
Zurück zum Zitat Verstappen SM et al (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(5):823–826 PubMedCrossRef Verstappen SM et al (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(5):823–826 PubMedCrossRef
554.
Zurück zum Zitat Jakobsson GL et al (2016) Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis 75(10):1838–1842 PubMedCrossRef Jakobsson GL et al (2016) Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Ann Rheum Dis 75(10):1838–1842 PubMedCrossRef
555.
Zurück zum Zitat van den Brandt S et al (2017) Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther 19(1):64 PubMedPubMedCentralCrossRef van den Brandt S et al (2017) Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther 19(1):64 PubMedPubMedCentralCrossRef
556.
Zurück zum Zitat Mahendira D et al (2014) Analysis of the effect of the oral contraceptive pill on clinical outcomes in women with ankylosing spondylitis. J Rheumatol 41(7):1344–1348 PubMedCrossRef Mahendira D et al (2014) Analysis of the effect of the oral contraceptive pill on clinical outcomes in women with ankylosing spondylitis. J Rheumatol 41(7):1344–1348 PubMedCrossRef
557.
Zurück zum Zitat Huang Z et al (2011) Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis. Clin Exp Rheumatol 29(4):642–649 PubMed Huang Z et al (2011) Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis. Clin Exp Rheumatol 29(4):642–649 PubMed
558.
Zurück zum Zitat Maugars Y et al (1996) Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 35(8):767–770 PubMedCrossRef Maugars Y et al (1996) Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 35(8):767–770 PubMedCrossRef
559.
Zurück zum Zitat Luukkainen R et al (1999) Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 17(1):88–90 PubMed Luukkainen R et al (1999) Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin Exp Rheumatol 17(1):88–90 PubMed
560.
Zurück zum Zitat Zheng Y et al (2014) Tomography-guided palisade sacroiliac joint radiofrequency neurotomy versus celecoxib for ankylosing spondylitis: a open-label, randomized, and controlled trial. Rheumatol Int 34(9):1195–1202 PubMedCrossRef Zheng Y et al (2014) Tomography-guided palisade sacroiliac joint radiofrequency neurotomy versus celecoxib for ankylosing spondylitis: a open-label, randomized, and controlled trial. Rheumatol Int 34(9):1195–1202 PubMedCrossRef
561.
Zurück zum Zitat Braun J et al (1996) Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 23(4):659–664 PubMed Braun J et al (1996) Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol 23(4):659–664 PubMed
562.
Zurück zum Zitat Vander Cruyssen B et al (2010) Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatol (oxford) 49(1):73–81 CrossRef Vander Cruyssen B et al (2010) Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatol (oxford) 49(1):73–81 CrossRef
563.
Zurück zum Zitat Lu MC et al (2017) Incident osteoarthritis and osteoarthritis-related joint replacement surgery in patients with ankylosing spondylitis: a secondary cohort analysis of a nationwide, population-based health claims database. PLoS ONE 12(11):e187594 PubMedPubMedCentralCrossRef Lu MC et al (2017) Incident osteoarthritis and osteoarthritis-related joint replacement surgery in patients with ankylosing spondylitis: a secondary cohort analysis of a nationwide, population-based health claims database. PLoS ONE 12(11):e187594 PubMedPubMedCentralCrossRef
564.
Zurück zum Zitat Bhan S, Eachempati KK, Malhotra R (2008) Primary cementless total hip arthroplasty for bony ankylosis in patients with ankylosing spondylitis. J Arthroplasty 23(6):859–866 PubMedCrossRef Bhan S, Eachempati KK, Malhotra R (2008) Primary cementless total hip arthroplasty for bony ankylosis in patients with ankylosing spondylitis. J Arthroplasty 23(6):859–866 PubMedCrossRef
565.
Zurück zum Zitat Kiaer T, Gehrchen M (2010) Transpedicular closed wedge osteotomy in ankylosing spondylitis: results of surgical treatment and prospective outcome analysis. Eur Spine J 19(1):57–64 PubMedCrossRef Kiaer T, Gehrchen M (2010) Transpedicular closed wedge osteotomy in ankylosing spondylitis: results of surgical treatment and prospective outcome analysis. Eur Spine J 19(1):57–64 PubMedCrossRef
566.
Zurück zum Zitat Regel A et al (2017) Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e397 PubMedPubMedCentralCrossRef Regel A et al (2017) Efficacy and safety of non-pharmacological and non-biological pharmacological treatment: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e397 PubMedPubMedCentralCrossRef
567.
Zurück zum Zitat Pigge RR et al (2008) Effectiveness of preoperative planning in the restoration of balance and view in ankylosing spondylitis. Neurosurg Focus 24(1):E7 PubMedCrossRef Pigge RR et al (2008) Effectiveness of preoperative planning in the restoration of balance and view in ankylosing spondylitis. Neurosurg Focus 24(1):E7 PubMedCrossRef
568.
Zurück zum Zitat Anwar F et al (2011) Delayed presentation and diagnosis of cervical spine injuries in long-standing ankylosing spondylitis. Eur Spine J 20(3):403–407 PubMedCrossRef Anwar F et al (2011) Delayed presentation and diagnosis of cervical spine injuries in long-standing ankylosing spondylitis. Eur Spine J 20(3):403–407 PubMedCrossRef
569.
Zurück zum Zitat Hoh DJ, Khoueir P, Wang MY (2008) Management of cervical deformity in ankylosing spondylitis. Neurosurg Focus 24(1):E9 PubMedCrossRef Hoh DJ, Khoueir P, Wang MY (2008) Management of cervical deformity in ankylosing spondylitis. Neurosurg Focus 24(1):E9 PubMedCrossRef
570.
571.
Zurück zum Zitat Thumbikat P et al (2007) Spinal cord injury in patients with ankylosing spondylitis: a 10-year review. Spine (phila Pa 1976) 32(26):2989–2995 CrossRef Thumbikat P et al (2007) Spinal cord injury in patients with ankylosing spondylitis: a 10-year review. Spine (phila Pa 1976) 32(26):2989–2995 CrossRef
572.
Zurück zum Zitat Whang PG et al (2009) The management of spinal injuries in patients with ankylosing spondylitis or diffuse idiopathic skeletal hyperostosis: a comparison of treatment methods and clinical outcomes. J Spinal Disord Tech 22(2):77–85 PubMedCrossRef Whang PG et al (2009) The management of spinal injuries in patients with ankylosing spondylitis or diffuse idiopathic skeletal hyperostosis: a comparison of treatment methods and clinical outcomes. J Spinal Disord Tech 22(2):77–85 PubMedCrossRef
574.
Zurück zum Zitat Ayhan F, Gecene M, Gündüz R (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and Ankylosing Spondylitis. Turk J Rheumatol 26:135–142 CrossRef Ayhan F, Gecene M, Gündüz R (2011) Long-term effects of comprehensive inpatient rehabilitation on function and disease activity in patients with chronic rheumatoid arthritis and Ankylosing Spondylitis. Turk J Rheumatol 26:135–142 CrossRef
575.
Zurück zum Zitat Staalesen Strumse YA et al (2011) Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting. J Rehabil Med 43(6):534–542 PubMedCrossRef Staalesen Strumse YA et al (2011) Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting. J Rehabil Med 43(6):534–542 PubMedCrossRef
576.
Zurück zum Zitat Masiero S et al (2011) Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol 38(7):1335–1342 PubMedCrossRef Masiero S et al (2011) Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol 38(7):1335–1342 PubMedCrossRef
577.
Zurück zum Zitat Van Tubergen A et al (2002) Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 47(5):459–467 PubMedCrossRef Van Tubergen A et al (2002) Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 47(5):459–467 PubMedCrossRef
578.
Zurück zum Zitat Mau W, Muller A (2008) Rehabilitation and outpatient physiotherapy in rheumatic disease patients. Results of cross-sectional studies of patients with rheumatoid arthritis or ankylosing spondylitis and rheumatologists. Z Rheumatol 67(7):542–553 PubMedCrossRef Mau W, Muller A (2008) Rehabilitation and outpatient physiotherapy in rheumatic disease patients. Results of cross-sectional studies of patients with rheumatoid arthritis or ankylosing spondylitis and rheumatologists. Z Rheumatol 67(7):542–553 PubMedCrossRef
579.
Zurück zum Zitat Boonen A et al (2010) ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 69(1):102–107 PubMedCrossRef Boonen A et al (2010) ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis 69(1):102–107 PubMedCrossRef
580.
Zurück zum Zitat Boonen A et al (2009) Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatol (oxford) 48(8):997–1002 CrossRef Boonen A et al (2009) Aspects relevant for functioning in patients with ankylosing spondylitis according to the health professionals: a Delphi study with the ICF as reference. Rheumatol (oxford) 48(8):997–1002 CrossRef
581.
Zurück zum Zitat van Echteld I et al (2006) Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 33(12):2475–2483 PubMed van Echteld I et al (2006) Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 33(12):2475–2483 PubMed
582.
Zurück zum Zitat Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247–255 PubMedCrossRef Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247–255 PubMedCrossRef
583.
Zurück zum Zitat Boonen A et al (2009) Which aspects of functioning are relevant for patients with ankylosing spondylitis: results of focus group interviews. J Rheumatol 36(11):2501–2511 PubMedCrossRef Boonen A et al (2009) Which aspects of functioning are relevant for patients with ankylosing spondylitis: results of focus group interviews. J Rheumatol 36(11):2501–2511 PubMedCrossRef
584.
Zurück zum Zitat Sigl T et al (2005) ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 64(11):1576–1581 PubMedPubMedCentralCrossRef Sigl T et al (2005) ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 64(11):1576–1581 PubMedPubMedCentralCrossRef
585.
Zurück zum Zitat Gordeev VS et al (2010) Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis 69(1):108–112 PubMedCrossRef Gordeev VS et al (2010) Role of contextual factors in health-related quality of life in ankylosing spondylitis. Ann Rheum Dis 69(1):108–112 PubMedCrossRef
586.
Zurück zum Zitat van Genderen S et al (2016) Social role participation in patients with Ankylosing Spondylitis: a cross-sectional comparison with population controls. Arthritis Care Res (hoboken) 68(12):1899–1905 CrossRef van Genderen S et al (2016) Social role participation in patients with Ankylosing Spondylitis: a cross-sectional comparison with population controls. Arthritis Care Res (hoboken) 68(12):1899–1905 CrossRef
587.
Zurück zum Zitat Zink A, Mau W, Schneider M (2001) Epidemiologische und sozialmedizinische Aspekte entzündlich-rheumatischer Systemerkrankungen. Internist (Berl) 42(2):211–222 CrossRef Zink A, Mau W, Schneider M (2001) Epidemiologische und sozialmedizinische Aspekte entzündlich-rheumatischer Systemerkrankungen. Internist (Berl) 42(2):211–222 CrossRef
588.
Zurück zum Zitat Ward MM, Kuzis S (2001) Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 28(2):315–321 PubMed Ward MM, Kuzis S (2001) Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol 28(2):315–321 PubMed
589.
Zurück zum Zitat Cakar E et al (2009) Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol 28(11):1309–1314 PubMedCrossRef Cakar E et al (2009) Work disability in ankylosing spondylitis: differences among working and work-disabled patients. Clin Rheumatol 28(11):1309–1314 PubMedCrossRef
590.
Zurück zum Zitat Boonen A et al (2002) Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 61(5):429–437 PubMedPubMedCentralCrossRef Boonen A et al (2002) Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 61(5):429–437 PubMedPubMedCentralCrossRef
591.
Zurück zum Zitat Boonen A et al (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60(4):353–358 PubMedPubMedCentralCrossRef Boonen A et al (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60(4):353–358 PubMedPubMedCentralCrossRef
592.
Zurück zum Zitat Castillo-Ortiz JD et al (2016) Work outcome in patients with Ankylosing Spondylitis: results from a 12-year followup of an international study. Arthritis Care Res (hoboken) 68(4):544–552 CrossRef Castillo-Ortiz JD et al (2016) Work outcome in patients with Ankylosing Spondylitis: results from a 12-year followup of an international study. Arthritis Care Res (hoboken) 68(4):544–552 CrossRef
593.
Zurück zum Zitat Bönisch A et al (2005) Evaluation eines Schulungsprogramms für Patienten mit Spondylitis ankylosans. In: Pertermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. S Roderer, Regensburg, S 51–102 Bönisch A et al (2005) Evaluation eines Schulungsprogramms für Patienten mit Spondylitis ankylosans. In: Pertermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. S Roderer, Regensburg, S 51–102
594.
Zurück zum Zitat Krauth C et al (2005) Gesundheitsökonomische Evaluation eines Patientenschulungsprogramms Spondylitis ankylosans in der stationären Rehabilitation. In: Petermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. S Roderer, Regensburg, S 103–143 Krauth C et al (2005) Gesundheitsökonomische Evaluation eines Patientenschulungsprogramms Spondylitis ankylosans in der stationären Rehabilitation. In: Petermann F (Hrsg) Prädiktion, Verfahrensoptimierung und Kosten in der medizinischen Rehabilitation. S Roderer, Regensburg, S 103–143
595.
Zurück zum Zitat Mau W, Ehlebracht-Konig I (2013) Rehabilitation in axial spondyloarthritides. Rehabilitation (Stuttg) 52(1):51–62 CrossRef Mau W, Ehlebracht-Konig I (2013) Rehabilitation in axial spondyloarthritides. Rehabilitation (Stuttg) 52(1):51–62 CrossRef
596.
Zurück zum Zitat Rodriguez-Lozano C et al (2013) Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomized study. Clin Exp Rheumatol 31(5):739–748 PubMed Rodriguez-Lozano C et al (2013) Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomized study. Clin Exp Rheumatol 31(5):739–748 PubMed
597.
Zurück zum Zitat Mattey DL et al (2011) Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. J Rheumatol 38(12):2608–2615 PubMedCrossRef Mattey DL et al (2011) Relationship between smoking and patient-reported measures of disease outcome in ankylosing spondylitis. J Rheumatol 38(12):2608–2615 PubMedCrossRef
598.
Zurück zum Zitat Zhao S et al (2017) Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatol Int 37(2):239–244 PubMedCrossRef Zhao S et al (2017) Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. Rheumatol Int 37(2):239–244 PubMedCrossRef
599.
Zurück zum Zitat Ward MM et al (2009) Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 61(7):859–866 PubMedPubMedCentralCrossRef Ward MM et al (2009) Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheum 61(7):859–866 PubMedPubMedCentralCrossRef
600.
Zurück zum Zitat Dougados M et al (2011) The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine 78(6):598–603 PubMedCrossRef Dougados M et al (2011) The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine 78(6):598–603 PubMedCrossRef
601.
Zurück zum Zitat Chung HY et al (2012) Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 71(6):809–816 PubMedCrossRef Chung HY et al (2012) Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 71(6):809–816 PubMedCrossRef
602.
Zurück zum Zitat Feldtkeller E (2002) Do patient self-help organizations help? Best Pract Res Clin Rheumatol 16(4):667–673 PubMedCrossRef Feldtkeller E (2002) Do patient self-help organizations help? Best Pract Res Clin Rheumatol 16(4):667–673 PubMedCrossRef
Metadaten
Titel
Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019
Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh) und der beteiligten medizinisch-wissenschaftlichen Fachgesellschaften und weiterer Organisationen*
verfasst von
PD Dr. med. U. Kiltz
Prof. Dr. med. J. Braun
Prof. Dr. med. A. Becker
Prof. Dr. med. J.-F. Chenot
PD Dr. med. M. Dreimann
L. Hammel
Prof. Dr. med. A. Heiligenhaus
PD Dr. med. K.‑G. Hermann
Prof. Dr. med. Dipl. Phys. R. Klett
PD Dr. med. D. Krause
Prof. Dr. med. K.‑F. Kreitner
Prof. Dr. med. U. Lange
A. Lauterbach
Prof. Dr. med. W. Mau
Prof. Dr. med. R. Mössner
Dr. med. U. Oberschelp
Dr. med. S. Philipp
Prof. Dr. med. U. Pleyer
Prof. Dr. med. M. Rudwaleit
Dr. med. E. Schneider
Prof. Dr. med. T. L. Schulte
Prof. Dr. med. em. J. Sieper
Prof. Dr. med. A. Stallmach
Prof. Dr. med. B. Swoboda
Prof. Dr. med. M. Winking
DGRh
DEGAM
DWG
DVMB
DOG
DRG
DGMM
DGPMR/DGRW
Physio Deutschland
DDG
DGOOC
DGIM
DGOOC/DGORh
DGNC
Publikationsdatum
01.12.2019
Verlag
Springer Medizin
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 1/2019
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-019-0670-3

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.